| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.939 | 0.001 | 0.939 | Anesthetic general | 0.227 0.061 DBMET00531 0.473 0.01 DBMET00532 0.698 0.003 DBMET00625 0.216 0.066 DBMET00489 | ||
| 0.784 | 0.002 | 0.784 | Vanilloid agonist | 0.279 0.005 DBMET00532 0.515 0.003 DBMET00625 | ||
| 0.729 | 0.026 | 0.729 | Apoptosis agonist | 0.28 0.187 DBMET00532 0.531 0.065 DBMET00625 | ||
| 0.681 | 0.005 | 0.681 | Tumour necrosis factor alpha release inhibitor | 0.221 0.092 DBMET00532 | ||
| 0.67 | 0.005 | 0.67 | Apoptosis antagonist | 0.501 0.02 DBMET00625 | ||
| 0.625 | 0.003 | 0.625 | Potassium channel large-conductance Ca-activated activator | 0.253 0.005 DBMET00532 0.136 0.013 DBMET00625 | ||
| 0.623 | 0.002 | 0.623 | Vanilloid 1 agonist | 0.129 0.068 DBMET00531 0.181 0.018 DBMET00532 0.321 0.004 DBMET00625 0.125 0.075 DBMET00489 | ||
| 0.564 | 0.018 | 0.601 | Immunosuppressant | 0.601 0.013 DBMET00532 0.407 0.06 DBMET00625 0.326 0.099 DBMET00489 | DBMET00532 | |
| 0.514 | 0.003 | 0.514 | Cyclooxygenase 3 inhibitor | 0.143 0.055 DBMET00531 0.205 0.017 DBMET00532 0.204 0.017 DBMET00625 0.131 0.066 DBMET00489 | ||
| 0.571 | 0.062 | 0.7 | Antiinflammatory | 0.7 0.031 DBMET00625 | DBMET00625 | |
| 0.518 | 0.01 | 0.518 | RNA-directed DNA polymerase inhibitor | 0.268 0.041 DBMET00531 0.453 0.014 DBMET00532 0.357 0.023 DBMET00625 0.264 0.042 DBMET00489 | ||
| 0.508 | 0.007 | 0.508 | Transcription factor STAT inhibitor | 0.386 0.022 DBMET00532 0.27 0.074 DBMET00625 | ||
| 0.482 | 0.014 | 0.66 | Hypolipemic | 0.66 0.005 DBMET00625 | DBMET00625 | |
| 0.476 | 0.014 | 0.592 | Antimitotic | 0.592 0.008 DBMET00532 | DBMET00532 | |
| 0.47 | 0.009 | 0.47 | Transcription factor STAT3 inhibitor | 0.368 0.027 DBMET00532 0.256 0.079 DBMET00625 | ||
| 0.496 | 0.061 | 0.646 | Caspase 9 stimulant | 0.429 0.095 DBMET00531 0.646 0.03 DBMET00532 0.534 0.049 DBMET00625 0.391 0.117 DBMET00489 | DBMET00532 | |
| 0.447 | 0.022 | 0.447 | Antiamyloidogenic | 0.187 0.109 DBMET00532 0.301 0.052 DBMET00625 | ||
| 0.427 | 0.004 | 0.427 | Potassium channel (Ca-activated) activator | 0.162 0.024 DBMET00532 0.208 0.013 DBMET00625 | ||
| 0.453 | 0.052 | 0.453 | Transcription factor NF kappa B inhibitor | 0.249 0.128 DBMET00532 0.437 0.056 DBMET00625 | ||
| 0.371 | 0.011 | 0.58 | Bone formation stimulant | 0.58 0.004 DBMET00532 0.141 0.066 DBMET00625 | DBMET00532 | |
| 0.385 | 0.038 | 0.581 | Antioxidant | 0.581 0.013 DBMET00625 | DBMET00625 | |
| 0.346 | 0.004 | 0.775 | Sphingosine 1-phosphate receptor 2 agonist | 0.775 0.002 DBMET00532 | DBMET00532 | |
| 0.345 | 0.004 | 0.42 | Catenin beta inhibitor | 0.42 0.004 DBMET00532 | DBMET00532 | |
| 0.376 | 0.035 | 0.476 | Calcium channel activator | 0.355 0.046 DBMET00531 0.476 0.007 DBMET00532 0.394 0.027 DBMET00625 0.319 0.073 DBMET00489 | DBMET00532 | |
| 0.353 | 0.012 | 0.356 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.243 0.046 DBMET00531 0.356 0.012 DBMET00532 0.302 0.023 DBMET00625 0.239 0.048 DBMET00489 | DBMET00532 | |
| 0.343 | 0.005 | 0.343 | Beta amyloid protein antagonist | 0.194 0.019 DBMET00532 0.148 0.042 DBMET00625 | ||
| 0.365 | 0.029 | 0.365 | Pyruvate kinase inhibitor | 0.319 0.043 DBMET00532 0.195 0.084 DBMET00625 | ||
| 0.335 | 0.005 | 0.335 | GABA receptor agonist | 0.117 0.06 DBMET00532 0.237 0.012 DBMET00625 0.157 0.032 DBMET00489 | ||
| 0.332 | 0.002 | 0.654 | Sphingosine 1-phosphate receptor 3 agonist | 0.654 0.001 DBMET00532 | DBMET00532 | |
| 0.334 | 0.004 | 0.464 | Triose-phosphate isomerase inhibitor | 0.274 0.005 DBMET00531 0.464 0.003 DBMET00532 0.237 0.008 DBMET00625 0.31 0.005 DBMET00489 | DBMET00532 | |
| 0.342 | 0.015 | 0.373 | Phospholipase C inhibitor | 0.18 0.061 DBMET00531 0.373 0.012 DBMET00532 0.355 0.014 DBMET00625 0.185 0.056 DBMET00489 | DBMET00532 | |
| 0.406 | 0.082 | 0.406 | Analgesic | |||
| 0.327 | 0.004 | 0.327 | Histone deacetylase SIRT1 stimulant | |||
| 0.327 | 0.004 | 0.327 | Histone deacetylase stimulant | |||
| 0.326 | 0.004 | 0.326 | Keratolytic | 0.096 0.033 DBMET00531 0.173 0.011 DBMET00532 0.192 0.009 DBMET00625 0.105 0.028 DBMET00489 | ||
| 0.337 | 0.014 | 0.523 | Lipid peroxidase inhibitor | 0.523 0.005 DBMET00625 | DBMET00625 | |
| 0.33 | 0.009 | 0.707 | DNA polymerase I inhibitor | 0.707 0.001 DBMET00532 0.121 0.067 DBMET00625 | DBMET00532 | |
| 0.33 | 0.01 | 0.33 | Phospholipase A2 inhibitor | 0.19 0.048 DBMET00532 0.213 0.036 DBMET00625 | ||
| 0.344 | 0.032 | 0.396 | DNA synthesis inhibitor | 0.26 0.06 DBMET00531 0.396 0.022 DBMET00532 0.26 0.06 DBMET00625 0.269 0.056 DBMET00489 | DBMET00532 | |
| 0.312 | 0.002 | 0.331 | Purinergic P2X2 antagonist | 0.331 0.001 DBMET00532 0.311 0.002 DBMET00625 | DBMET00532 | |
| 0.315 | 0.006 | 0.476 | Aminoacyl-tRNA synthetase inhibitor | 0.476 0.003 DBMET00532 | DBMET00532 | |
| 0.312 | 0.003 | 0.312 | Sphingosine 1-phosphate receptor 2 antagonist | 0.143 0.05 DBMET00531 0.214 0.005 DBMET00532 0.192 0.01 DBMET00625 0.138 0.059 DBMET00489 | ||
| 0.314 | 0.009 | 0.443 | UDP-glucose 4-epimerase inhibitor | 0.309 0.01 DBMET00531 0.443 0.004 DBMET00532 0.249 0.013 DBMET00625 0.324 0.009 DBMET00489 | DBMET00532 | |
| 0.3 | 0.005 | 0.321 | Mannose-6-phosphate isomerase inhibitor | 0.199 0.031 DBMET00531 0.321 0.005 DBMET00532 0.245 0.013 DBMET00625 0.188 0.038 DBMET00489 | DBMET00532 | |
| 0.288 | 0.007 | 0.429 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.248 0.01 DBMET00531 0.429 0.003 DBMET00532 0.191 0.017 DBMET00625 0.267 0.008 DBMET00489 | DBMET00532 | |
| 0.285 | 0.005 | 0.42 | Purinergic P2 antagonist | 0.42 0.004 DBMET00532 | DBMET00532 | |
| 0.3 | 0.022 | 0.409 | Melanin inhibitor | 0.154 0.076 DBMET00531 0.2 0.041 DBMET00532 0.409 0.011 DBMET00625 0.156 0.074 DBMET00489 | DBMET00625 | |
| 0.332 | 0.07 | 0.332 | Immunostimulant | 0.33 0.07 DBMET00532 0.238 0.101 DBMET00625 | ||
| 0.253 | 0.019 | 0.253 | Alkaline phosphatase inhibitor | 0.179 0.043 DBMET00532 0.13 0.076 DBMET00625 | ||
| 0.279 | 0.046 | 0.279 | Anticonvulsant | |||
| 0.243 | 0.013 | 0.243 | Expectorant | 0.103 0.065 DBMET00531 0.198 0.021 DBMET00532 0.19 0.023 DBMET00625 0.111 0.058 DBMET00489 | ||
| 0.232 | 0.005 | 0.232 | Sphingosine 1-phosphate receptor 5 antagonist | 0.157 0.05 DBMET00531 0.225 0.005 DBMET00532 0.176 0.027 DBMET00625 0.156 0.051 DBMET00489 | ||
| 0.234 | 0.011 | 0.374 | Adenylate kinase inhibitor | 0.257 0.009 DBMET00531 0.374 0.004 DBMET00532 0.172 0.02 DBMET00625 0.276 0.008 DBMET00489 | DBMET00532 | |
| 0.249 | 0.027 | 0.252 | Protein kinase stimulant | 0.128 0.085 DBMET00531 0.236 0.03 DBMET00532 0.252 0.026 DBMET00625 0.132 0.082 DBMET00489 | DBMET00625 | |
| 0.231 | 0.009 | 0.557 | Porphobilinogen synthase inhibitor | 0.263 0.007 DBMET00531 0.557 0.003 DBMET00532 0.255 0.007 DBMET00625 0.301 0.005 DBMET00489 | DBMET00532 | |
| 0.226 | 0.005 | 0.226 | Sphingosine 1-phosphate receptor 4 antagonist | 0.125 0.064 DBMET00531 0.219 0.006 DBMET00532 0.143 0.04 DBMET00625 0.119 0.074 DBMET00489 | ||
| 0.303 | 0.086 | 0.347 | Antithrombotic | 0.347 0.065 DBMET00532 0.293 0.093 DBMET00625 | DBMET00532 | |
| 0.304 | 0.089 | 0.698 | Cholesterol antagonist | 0.303 0.089 DBMET00531 0.497 0.033 DBMET00532 0.698 0.008 DBMET00625 0.314 0.082 DBMET00489 | DBMET00625 | |
| 0.215 | 0.005 | 0.215 | Heat shock protein 70 antagonist | 0.149 0.049 DBMET00531 0.199 0.006 DBMET00532 0.159 0.029 DBMET00625 0.145 0.059 DBMET00489 | ||
| 0.214 | 0.004 | 0.379 | Acetyl-CoA transferase inhibitor | 0.379 0.003 DBMET00625 | DBMET00625 | |
| 0.303 | 0.095 | 0.495 | Vasodilator, peripheral | 0.226 0.148 DBMET00531 0.403 0.054 DBMET00532 0.495 0.029 DBMET00625 0.21 0.164 DBMET00489 | DBMET00625 | |
| 0.209 | 0.003 | 0.209 | Sphingosine 1-phosphate receptor 3 antagonist | 0.108 0.006 DBMET00532 0.078 0.018 DBMET00625 | ||
| 0.298 | 0.093 | 0.298 | Angiogenesis inhibitor | |||
| 0.261 | 0.068 | 0.261 | Platelet antagonist | 0.15 0.145 DBMET00532 0.149 0.145 DBMET00625 | ||
| 0.192 | 0.004 | 0.192 | Sphingosine 1-phosphate receptor antagonist | 0.11 0.016 DBMET00532 0.084 0.038 DBMET00625 | ||
| 0.188 | 0.004 | 0.671 | Sphingosine 1-phosphate receptor 5 agonist | 0.671 0.002 DBMET00532 | DBMET00532 | |
| 0.283 | 0.102 | 0.36 | Vasodilator, coronary | 0.249 0.136 DBMET00531 0.328 0.067 DBMET00532 0.36 0.051 DBMET00625 0.222 0.161 DBMET00489 | DBMET00625 | |
| 0.206 | 0.027 | 0.241 | Arachidonic acid antagonist | 0.212 0.023 DBMET00531 0.236 0.009 DBMET00532 0.241 0.008 DBMET00625 0.213 0.022 DBMET00489 | DBMET00625 | |
| 0.303 | 0.133 | 0.363 | Antibacterial | 0.287 0.145 DBMET00532 0.363 0.095 DBMET00625 0.298 0.137 DBMET00489 | DBMET00625 | |
| 0.258 | 0.088 | 0.357 | Spasmolytic | 0.184 0.133 DBMET00532 0.357 0.05 DBMET00625 | DBMET00625 | |
| 0.183 | 0.013 | 0.273 | Folate antagonist | 0.273 0.004 DBMET00532 0.11 0.049 DBMET00625 | DBMET00532 | |
| 0.223 | 0.055 | 0.393 | Non-steroidal antiinflammatory agent | 0.235 0.049 DBMET00532 0.393 0.014 DBMET00625 | DBMET00625 | |
| 0.177 | 0.013 | 0.436 | NADH dehydrogenase inhibitor | 0.229 0.009 DBMET00531 0.436 0.004 DBMET00532 0.157 0.016 DBMET00625 0.249 0.008 DBMET00489 | DBMET00532 | |
| 0.198 | 0.036 | 0.261 | Hexokinase inhibitor | 0.142 0.088 DBMET00531 0.261 0.015 DBMET00532 0.188 0.043 DBMET00625 0.145 0.085 DBMET00489 | DBMET00532 | |
| 0.167 | 0.015 | 0.317 | Phosphofructokinase-1 inhibitor | 0.205 0.011 DBMET00531 0.317 0.005 DBMET00532 0.139 0.02 DBMET00625 0.227 0.009 DBMET00489 | DBMET00532 | |
| 0.165 | 0.015 | 0.229 | DOPA decarboxylase inhibitor | 0.166 0.015 DBMET00531 0.229 0.004 DBMET00532 0.168 0.014 DBMET00625 0.172 0.012 DBMET00489 | DBMET00532 | |
| 0.159 | 0.01 | 0.269 | Argininosuccinate synthase inhibitor | 0.157 0.011 DBMET00531 0.269 0.005 DBMET00532 0.113 0.016 DBMET00625 0.177 0.009 DBMET00489 | DBMET00532 | |
| 0.177 | 0.033 | 0.259 | Cholesterol synthesis inhibitor | 0.124 0.061 DBMET00531 0.244 0.019 DBMET00532 0.256 0.017 DBMET00625 0.259 0.016 DBMET00489 | DBMET00489 | |
| 0.162 | 0.02 | 0.207 | Sphingomyelinase inhibitor | 0.113 0.047 DBMET00531 0.207 0.008 DBMET00532 0.097 0.063 DBMET00625 0.107 0.052 DBMET00489 | DBMET00532 | |
| 0.175 | 0.035 | 0.525 | Aldehyde dehydrogenase inhibitor | 0.525 0.004 DBMET00531 0.305 0.011 DBMET00532 0.191 0.03 DBMET00625 0.144 0.051 DBMET00489 | DBMET00531 | |
| 0.164 | 0.025 | 0.198 | Mucolytic | 0.132 0.045 DBMET00531 0.198 0.014 DBMET00532 0.198 0.014 DBMET00625 0.14 0.039 DBMET00489 | DBMET00625 | |
| 0.148 | 0.009 | 0.321 | Biliverdin reductase inhibitor | 0.19 0.006 DBMET00531 0.321 0.003 DBMET00532 0.107 0.016 DBMET00625 0.212 0.005 DBMET00489 | DBMET00532 | |
| 0.153 | 0.015 | 0.337 | Glutamate dehydrogenase inhibitor | 0.176 0.012 DBMET00531 0.337 0.005 DBMET00532 0.128 0.02 DBMET00625 0.203 0.01 DBMET00489 | DBMET00532 | |
| 0.156 | 0.019 | 0.195 | Transcription factor STAT6 inhibitor | 0.111 0.077 DBMET00531 0.195 0.008 DBMET00532 0.132 0.042 DBMET00625 | DBMET00532 | |
| 0.155 | 0.019 | 0.454 | Toll-Like receptor 4 antagonist | 0.454 0.002 DBMET00532 | DBMET00532 | |
| 0.147 | 0.012 | 0.161 | Ornithine decarboxylase inhibitor | 0.096 0.048 DBMET00531 0.131 0.019 DBMET00532 0.161 0.008 DBMET00625 0.099 0.046 DBMET00489 | DBMET00625 | |
| 0.139 | 0.016 | 0.188 | Glutamate (mGluR7) agonist | 0.121 0.03 DBMET00531 0.188 0.005 DBMET00532 0.108 0.045 DBMET00625 0.104 0.053 DBMET00489 | DBMET00532 | |
| 0.125 | 0.003 | 0.276 | Purinergic P2Y2 antagonist | 0.276 0.001 DBMET00532 | DBMET00532 | |
| 0.156 | 0.034 | 0.171 | Microtubule formation inhibitor | 0.127 0.053 DBMET00531 0.171 0.028 DBMET00532 0.162 0.032 DBMET00625 0.123 0.058 DBMET00489 | DBMET00532 | |
| 0.163 | 0.044 | 0.236 | Adenylate cyclase stimulant | 0.185 0.022 DBMET00531 0.236 0.005 DBMET00532 0.209 0.01 DBMET00625 0.185 0.022 DBMET00489 | DBMET00532 | |
| 0.136 | 0.019 | 0.173 | GABA A receptor agonist | 0.08 0.063 DBMET00532 0.173 0.013 DBMET00625 0.102 0.035 DBMET00489 | DBMET00625 | |
| 0.175 | 0.059 | 0.728 | Interleukin 6 antagonist | 0.219 0.031 DBMET00625 0.728 0.002 DBMET00489 | DBMET00489 | |
| 0.156 | 0.044 | 0.193 | Alkylator | 0.193 0.028 DBMET00532 0.143 0.05 DBMET00625 | DBMET00532 | |
| 0.12 | 0.011 | 0.268 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.142 0.009 DBMET00531 0.268 0.005 DBMET00532 0.086 0.018 DBMET00625 0.154 0.008 DBMET00489 | DBMET00532 | |
| 0.12 | 0.012 | 0.182 | Purinergic P2X1 antagonist | 0.11 0.014 DBMET00531 0.182 0.004 DBMET00532 0.112 0.013 DBMET00625 0.114 0.013 DBMET00489 | DBMET00532 | |
| 0.123 | 0.015 | 0.366 | Carbamoyl phosphate synthetase inhibitor | 0.196 0.008 DBMET00531 0.366 0.004 DBMET00532 0.093 0.023 DBMET00625 0.222 0.006 DBMET00489 | DBMET00532 | |
| 0.136 | 0.029 | 0.418 | DNA directed RNA polymerase inhibitor | 0.418 0.005 DBMET00532 | DBMET00532 | |
| 0.206 | 0.1 | 0.229 | Vasodilator | 0.155 0.15 DBMET00532 0.182 0.12 DBMET00625 0.229 0.083 DBMET00489 | DBMET00489 | |
| 0.212 | 0.108 | 0.275 | Cardiotonic | 0.275 0.067 DBMET00489 | DBMET00489 | |
| 0.111 | 0.008 | 0.111 | Purinergic P2Y antagonist | 0.084 0.012 DBMET00532 0.05 0.027 DBMET00625 | ||
| 0.189 | 0.086 | 0.322 | Psychostimulant | 0.322 0.037 DBMET00532 0.143 0.123 DBMET00625 | DBMET00532 | |
| 0.105 | 0.003 | 0.105 | Geranyltranstransferase inhibitor | 0.055 0.018 DBMET00531 0.093 0.004 DBMET00532 0.095 0.004 DBMET00625 0.058 0.015 DBMET00489 | ||
| 0.162 | 0.061 | 0.162 | CDC-like kinase 1 inhibitor | |||
| 0.105 | 0.004 | 0.105 | Purinergic P2X3 antagonist | 0.073 0.005 DBMET00625 | ||
| 0.108 | 0.008 | 0.166 | Glutamate (mGluR6) antagonist | 0.107 0.008 DBMET00531 0.166 0.003 DBMET00532 0.092 0.015 DBMET00625 0.114 0.007 DBMET00489 | DBMET00532 | |
| 0.126 | 0.027 | 0.154 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.078 0.053 DBMET00531 0.151 0.019 DBMET00532 0.154 0.018 DBMET00625 0.078 0.053 DBMET00489 | DBMET00625 | |
| 0.145 | 0.049 | 0.236 | Adenylate cyclase inhibitor | 0.096 0.088 DBMET00531 0.236 0.021 DBMET00532 0.135 0.056 DBMET00625 | DBMET00532 | |
| 0.107 | 0.012 | 0.341 | Autotaxin inhibitor | 0.341 0.004 DBMET00532 | DBMET00532 | |
| 0.127 | 0.033 | 0.175 | Anabolic | 0.141 0.023 DBMET00531 0.166 0.011 DBMET00532 0.145 0.021 DBMET00625 0.175 0.008 DBMET00489 | DBMET00489 | |
| 0.111 | 0.019 | 0.154 | D-Ala-D-Ala ligase inhibitor | 0.108 0.021 DBMET00531 0.154 0.005 DBMET00532 0.12 0.014 DBMET00625 0.11 0.02 DBMET00489 | DBMET00532 | |
| 0.106 | 0.015 | 0.247 | Acyl-CoA dehydrogenase inhibitor | 0.181 0.006 DBMET00531 0.247 0.003 DBMET00532 0.094 0.018 DBMET00625 0.187 0.006 DBMET00489 | DBMET00532 | |
| 0.099 | 0.01 | 0.402 | Potassium channel (Ca-activated) blocker | 0.402 0.003 DBMET00532 | DBMET00532 | |
| 0.111 | 0.022 | 0.155 | CDC25A inhibitor | 0.097 0.029 DBMET00532 0.155 0.012 DBMET00625 | DBMET00625 | |
| 0.13 | 0.043 | 0.293 | GABA C receptor antagonist | 0.235 0.008 DBMET00531 0.293 0.005 DBMET00532 0.256 0.006 DBMET00625 0.228 0.009 DBMET00489 | DBMET00532 | |
| 0.09 | 0.004 | 0.569 | Purinergic P2X agonist | 0.569 0.001 DBMET00532 | DBMET00532 | |
| 0.101 | 0.017 | 0.165 | TRPA1 antagonist | 0.078 0.027 DBMET00532 0.165 0.008 DBMET00625 | DBMET00625 | |
| 0.141 | 0.059 | 0.225 | Toll-Like receptor 2 antagonist | 0.14 0.059 DBMET00531 0.225 0.014 DBMET00532 0.168 0.041 DBMET00625 0.142 0.058 DBMET00489 | DBMET00532 | |
| 0.105 | 0.023 | 0.17 | Sphingosine 1-phosphate receptor 4 agonist | 0.07 0.044 DBMET00531 0.17 0.005 DBMET00532 0.069 0.045 DBMET00489 | DBMET00532 | |
| 0.088 | 0.007 | 0.167 | Glucose-6-phosphate isomerase inhibitor | 0.111 0.004 DBMET00531 0.167 0.002 DBMET00532 0.072 0.012 DBMET00625 0.121 0.003 DBMET00489 | DBMET00532 | |
| 0.114 | 0.033 | 0.126 | Polo-like kinase-1 inhibitor | 0.126 0.027 DBMET00532 | DBMET00532 | |
| 0.109 | 0.03 | 0.13 | Glutathione S-transferase inhibitor | 0.078 0.065 DBMET00531 0.13 0.018 DBMET00532 0.118 0.024 DBMET00625 0.074 0.073 DBMET00489 | DBMET00532 | |
| 0.084 | 0.007 | 0.101 | Retinoid X receptor agonist | 0.059 0.014 DBMET00532 0.101 0.005 DBMET00625 0.036 0.024 DBMET00489 | DBMET00625 | |
| 0.084 | 0.008 | 0.103 | Lysophosphatidic acid 3 receptor antagonist | 0.063 0.019 DBMET00531 0.103 0.005 DBMET00532 0.047 0.04 DBMET00625 0.064 0.019 DBMET00489 | DBMET00532 | |
| 0.216 | 0.145 | 0.216 | Immunomodulator | |||
| 0.102 | 0.031 | 0.337 | Histidine decarboxylase inhibitor | 0.16 0.018 DBMET00531 0.337 0.005 DBMET00532 0.119 0.026 DBMET00625 0.184 0.015 DBMET00489 | DBMET00532 | |
| 0.072 | 0.003 | 0.378 | Purinergic P2Y1 antagonist | 0.378 0.001 DBMET00532 | DBMET00532 | |
| 0.074 | 0.008 | 0.081 | Purinergic P2X4 antagonist | 0.042 0.041 DBMET00531 0.081 0.006 DBMET00532 0.06 0.015 DBMET00625 | DBMET00532 | |
| 0.089 | 0.025 | 0.089 | Bcl2 antagonist | |||
| 0.074 | 0.011 | 0.17 | Antiviral (Hepatitis D) | 0.17 0.003 DBMET00532 | DBMET00532 | |
| 0.073 | 0.01 | 0.073 | Sphingosine 1-phosphate receptor agonist | 0.067 0.013 DBMET00532 | ||
| 0.07 | 0.008 | 0.07 | Sphingosine 1-phosphate receptor 1 agonist | 0.063 0.011 DBMET00532 0.04 0.033 DBMET00625 | ||
| 0.144 | 0.082 | 0.179 | Diuretic | 0.131 0.093 DBMET00532 0.179 0.054 DBMET00625 | DBMET00625 | |
| 0.085 | 0.025 | 0.085 | Ribonucleotide reductase inhibitor | 0.08 0.027 DBMET00532 0.054 0.04 DBMET00625 | ||
| 0.088 | 0.029 | 0.253 | GABA B receptor agonist | 0.094 0.022 DBMET00531 0.108 0.012 DBMET00532 0.253 0.003 DBMET00625 0.097 0.019 DBMET00489 | DBMET00625 | |
| 0.176 | 0.118 | 0.495 | Free radical scavenger | 0.495 0.017 DBMET00625 0.237 0.074 DBMET00489 | DBMET00625 | |
| 0.07 | 0.012 | 0.082 | Fructose-1,6-bisphosphatase inhibitor | 0.082 0.007 DBMET00532 0.042 0.035 DBMET00625 | DBMET00532 | |
| 0.066 | 0.009 | 0.213 | Fumarate hydratase inhibitor | 0.086 0.006 DBMET00531 0.213 0.003 DBMET00532 0.048 0.014 DBMET00625 0.105 0.005 DBMET00489 | DBMET00532 | |
| 0.06 | 0.004 | 0.345 | Inosine monophosphate dehydrogenase 1 inhibitor | 0.345 0.002 DBMET00532 | DBMET00532 | |
| 0.062 | 0.009 | 0.206 | Acetyl-CoA transferase 1 inhibitor | 0.206 0.003 DBMET00625 | DBMET00625 | |
| 0.062 | 0.01 | 0.079 | Guanylate cyclase inhibitor | 0.064 0.008 DBMET00531 0.079 0.003 DBMET00532 0.055 0.016 DBMET00625 0.066 0.007 DBMET00489 | DBMET00532 | |
| 0.062 | 0.011 | 0.119 | Retinoid X alpha receptor agonist | 0.034 0.025 DBMET00531 0.035 0.024 DBMET00532 0.119 0.004 DBMET00625 0.04 0.02 DBMET00489 | DBMET00625 | |
| 0.133 | 0.082 | 0.227 | Cell wall synthesis inhibitor | 0.139 0.076 DBMET00531 0.227 0.021 DBMET00532 0.152 0.064 DBMET00625 0.138 0.077 DBMET00489 | DBMET00532 | |
| 0.054 | 0.003 | 0.378 | Toll-Like receptor 4 agonist | 0.378 0.001 DBMET00532 | DBMET00532 | |
| 0.073 | 0.024 | 0.195 | Ornithine carbamoyltransferase inhibitor | 0.101 0.016 DBMET00531 0.195 0.007 DBMET00532 0.055 0.035 DBMET00625 0.116 0.013 DBMET00489 | DBMET00532 | |
| 0.053 | 0.004 | 0.964 | Growth factor receptor-bound protein 2 antagonist | 0.964 0.001 DBMET00532 | DBMET00532 | |
| 0.055 | 0.008 | 0.105 | Lysophosphatidic acid 2 receptor antagonist | 0.028 0.026 DBMET00531 0.105 0.004 DBMET00532 | DBMET00532 | |
| 0.066 | 0.019 | 0.127 | Adenine nucleotide translocase inhibitor | 0.127 0.003 DBMET00532 0.126 0.004 DBMET00625 | DBMET00532 | |
| 0.114 | 0.067 | 0.198 | Protein-tyrosine phosphatase 1B inhibitor | 0.198 0.03 DBMET00625 | DBMET00625 | |
| 0.074 | 0.027 | 0.076 | Ribonucleoside-diphosphate reductase inhibitor | 0.076 0.026 DBMET00532 0.054 0.038 DBMET00625 | DBMET00532 | |
| 0.181 | 0.138 | 0.367 | Interleukin agonist | 0.262 0.07 DBMET00531 0.367 0.025 DBMET00532 0.3 0.048 DBMET00625 0.255 0.075 DBMET00489 | DBMET00532 | |
| 0.053 | 0.01 | 0.108 | Glutamate (mGluR8) agonist | 0.067 0.005 DBMET00531 0.108 0.003 DBMET00532 0.048 0.013 DBMET00625 0.073 0.005 DBMET00489 | DBMET00532 | |
| 0.046 | 0.003 | 0.807 | Purinergic P2 agonist | 0.807 0 DBMET00532 | DBMET00532 | |
| 0.046 | 0.003 | 0.807 | Purinergic receptor agonist | 0.807 0 DBMET00532 | DBMET00532 | |
| 0.069 | 0.027 | 0.122 | Heme oxygenase stimulant | 0.122 0.004 DBMET00625 | DBMET00625 | |
| 0.066 | 0.023 | 0.081 | Antimetabolite | 0.081 0.019 DBMET00532 | DBMET00532 | |
| 0.161 | 0.122 | 0.446 | Neurotrophic factor enhancer | 0.216 0.062 DBMET00531 0.236 0.047 DBMET00532 0.446 0.005 DBMET00625 0.211 0.067 DBMET00489 | DBMET00625 | |
| 0.054 | 0.017 | 0.094 | Glutamate (mGluR group III) antagonist | 0.044 0.03 DBMET00531 0.094 0.005 DBMET00532 0.047 0.025 DBMET00625 0.045 0.028 DBMET00489 | DBMET00532 | |
| 0.037 | 0.001 | 0.168 | Mannitol 2-dehydrogenase inhibitor | 0.168 0 DBMET00532 | DBMET00532 | |
| 0.04 | 0.005 | 0.047 | Retinoid X gamma receptor antagonist | 0.047 0.004 DBMET00625 | DBMET00625 | |
| 0.039 | 0.003 | 0.796 | Purinergic P2Y agonist | 0.796 0 DBMET00532 | DBMET00532 | |
| 0.07 | 0.035 | 0.119 | HIV-1 integrase (Strand Transfer) inhibitor | 0.119 0.017 DBMET00532 0.1 0.023 DBMET00625 | DBMET00532 | |
| 0.194 | 0.16 | 0.335 | Hypoxia-inducible factor 1 alpha inhibitor | 0.335 0.05 DBMET00625 | DBMET00625 | |
| 0.06 | 0.029 | 0.083 | Sphingosine 1-phosphate receptor 1 antagonist | 0.083 0.013 DBMET00532 | DBMET00532 | |
| 0.051 | 0.02 | 0.051 | Guanylate cyclase stimulant | |||
| 0.051 | 0.021 | 0.086 | AICAR transformylase inhibitor | 0.048 0.024 DBMET00531 0.086 0.006 DBMET00532 0.048 0.025 DBMET00625 0.049 0.023 DBMET00489 | DBMET00532 | |
| 0.173 | 0.142 | 0.26 | DNA damaging | 0.243 0.084 DBMET00532 0.26 0.075 DBMET00625 | DBMET00625 | |
| 0.044 | 0.015 | 0.068 | Vanilloid 3 antagonist | 0.042 0.018 DBMET00531 0.068 0.004 DBMET00532 0.056 0.005 DBMET00625 0.037 0.031 DBMET00489 | DBMET00532 | |
| 0.041 | 0.013 | 0.091 | HMG CoA reductase inhibitor | 0.057 0.005 DBMET00625 0.091 0.003 DBMET00489 | DBMET00489 | |
| 0.048 | 0.02 | 0.075 | Thymidine kinase inhibitor | 0.044 0.024 DBMET00531 0.075 0.009 DBMET00532 0.044 0.024 DBMET00625 0.044 0.024 DBMET00489 | DBMET00532 | |
| 0.105 | 0.079 | 0.474 | TRPA1 agonist | 0.117 0.062 DBMET00531 0.164 0.022 DBMET00532 0.474 0.003 DBMET00625 0.099 0.089 DBMET00489 | DBMET00625 | |
| 0.044 | 0.018 | 0.069 | Retinoid X receptor antagonist | 0.039 0.025 DBMET00531 0.04 0.024 DBMET00532 0.069 0.004 DBMET00625 0.042 0.02 DBMET00489 | DBMET00625 | |
| 0.043 | 0.017 | 0.096 | Phosphoglycerate kinase inhibitor | 0.037 0.022 DBMET00531 0.096 0.007 DBMET00532 0.032 0.028 DBMET00625 0.039 0.02 DBMET00489 | DBMET00532 | |
| 0.034 | 0.008 | 0.057 | Lysophosphatidic acid receptor 1 agonist | 0.032 0.009 DBMET00531 0.057 0.003 DBMET00532 0.033 0.009 DBMET00489 | DBMET00532 | |
| 0.083 | 0.06 | 0.125 | 3C-Like protease (SARS coronavirus) inhibitor | 0.125 0.017 DBMET00625 | DBMET00625 | |
| 0.111 | 0.089 | 0.399 | Tubulin antagonist | 0.399 0.012 DBMET00532 | DBMET00532 | |
| 0.046 | 0.024 | 0.08 | Alpha 1L adrenoreceptor agonist | 0.08 0.004 DBMET00625 | DBMET00625 | |
| 0.141 | 0.12 | 0.251 | Hepatoprotectant | 0.251 0.043 DBMET00625 | DBMET00625 | |
| 0.024 | 0.005 | 0.257 | Thyroid hormone alpha agonist | 0.257 0.002 DBMET00625 | DBMET00625 | |
| 0.145 | 0.126 | 0.275 | Angiogenesis stimulant | 0.275 0.059 DBMET00532 0.253 0.068 DBMET00625 | DBMET00532 | |
| 0.029 | 0.013 | 0.287 | Purinergic P2Y12 antagonist | 0.287 0.003 DBMET00532 | DBMET00532 | |
| 0.036 | 0.02 | 0.073 | Squalene synthetase inhibitor | 0.073 0.009 DBMET00532 | DBMET00532 | |
| 0.025 | 0.01 | 0.031 | Lysophosphatidic acid 1 receptor antagonist | 0.031 0.006 DBMET00532 | DBMET00532 | |
| 0.077 | 0.062 | 0.156 | Glycine receptor antagonist | 0.118 0.019 DBMET00531 0.156 0.006 DBMET00532 0.117 0.02 DBMET00625 0.109 0.025 DBMET00489 | DBMET00532 | |
| 0.019 | 0.006 | 0.048 | Lysophosphatidic acid receptor 3 agonist | 0.02 0.005 DBMET00531 0.048 0.002 DBMET00532 0.02 0.005 DBMET00489 | DBMET00532 | |
| 0.03 | 0.017 | 0.07 | Uridine phosphorylase inhibitor | 0.043 0.01 DBMET00531 0.07 0.004 DBMET00532 0.035 0.014 DBMET00625 0.046 0.009 DBMET00489 | DBMET00532 | |
| 0.04 | 0.027 | 0.046 | CF transmembrane conductance regulator antagonist | 0.038 0.034 DBMET00531 0.046 0.013 DBMET00532 0.042 0.021 DBMET00625 | DBMET00532 | |
| 0.029 | 0.018 | 0.078 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.047 0.01 DBMET00531 0.078 0.005 DBMET00532 0.044 0.01 DBMET00489 | DBMET00532 | |
| 0.024 | 0.014 | 0.039 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.039 0.004 DBMET00532 | DBMET00532 | |
| 0.03 | 0.02 | 0.037 | Complement C5a chemotactic receptor antagonist | 0.037 0.014 DBMET00625 | DBMET00625 | |
| 0.055 | 0.046 | 0.087 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.087 0.022 DBMET00532 0.086 0.022 DBMET00625 | DBMET00532 | |
| 0.067 | 0.06 | 0.295 | Glycine receptor agonist | 0.114 0.014 DBMET00531 0.111 0.015 DBMET00532 0.295 0.002 DBMET00625 0.114 0.014 DBMET00489 | DBMET00625 | |
| 0.019 | 0.012 | 0.029 | Methylmalonyl-CoA mutase inhibitor | 0.022 0.006 DBMET00531 0.029 0.003 DBMET00532 0.018 0.014 DBMET00625 0.022 0.006 DBMET00489 | DBMET00532 | |
| 0.083 | 0.076 | 0.568 | Breast cancer-resistant protein inhibitor | 0.568 0.004 DBMET00532 | DBMET00532 | |
| 0.05 | 0.044 | 0.112 | Alpha 1L adrenoreceptor antagonist | 0.112 0.004 DBMET00625 | DBMET00625 | |
| 0.034 | 0.029 | 0.059 | Inosine monophosphate dehydrogenase inhibitor | 0.059 0.011 DBMET00532 | DBMET00532 | |
| 0.035 | 0.03 | 0.054 | Farnesoid X receptor agonist | 0.054 0.013 DBMET00625 | DBMET00625 | |
| 0.015 | 0.011 | 0.03 | Purinergic P2Y1 agonist | 0.017 0.008 DBMET00531 0.03 0.004 DBMET00532 0.017 0.009 DBMET00489 | DBMET00532 | |
| 0.014 | 0.012 | 0.347 | Thyroid hormone alpha antagonist | 0.347 0.002 DBMET00625 | DBMET00625 | |
| 0.005 | 0.003 | 0.378 | Purinergic P2Y4 agonist | 0.378 0 DBMET00532 | DBMET00532 | |
| 0.011 | 0.01 | 0.038 | Glutamate (mGluR6) agonist | 0.017 0.005 DBMET00531 0.038 0.003 DBMET00532 0.011 0.01 DBMET00625 0.02 0.004 DBMET00489 | DBMET00532 | |
| 0.049 | 0.049 | 0.094 | Sphingosine kinase 2 inhibitor | 0.058 0.034 DBMET00531 0.094 0.009 DBMET00532 0.094 0.009 DBMET00625 0.058 0.034 DBMET00489 | DBMET00625 | |
| 0.005 | 0.004 | 0.005 | Bone morphogenic protein 1 inhibitor | |||
| 0.054 | 0.055 | 0.129 | HIV-1 integrase (3'-Processing) inhibitor | 0.129 0.017 DBMET00532 0.097 0.027 DBMET00625 | DBMET00532 | |
| 0.016 | 0.018 | 0.336 | Purinergic P2T antagonist | 0.336 0.003 DBMET00532 | DBMET00532 | |
| 0.056 | 0.058 | 0.099 | CDC25B inhibitor | 0.099 0.016 DBMET00625 | DBMET00625 | |
| 0.015 | 0.019 | 0.046 | Retinoic acid receptor antagonist | 0.046 0.004 DBMET00625 | DBMET00625 | |
| 0.034 | 0.038 | 0.07 | Membrane dipeptidase inhibitor | 0.051 0.015 DBMET00531 0.07 0.007 DBMET00532 0.038 0.029 DBMET00625 0.055 0.013 DBMET00489 | DBMET00532 | |
| 0.057 | 0.062 | 0.147 | HIV-1 reverse transcriptase inhibitor | 0.147 0.015 DBMET00532 | DBMET00532 | |
| 0.016 | 0.021 | 0.049 | Retinoic acid alpha receptor antagonist | 0.049 0.004 DBMET00625 | DBMET00625 | |
| 0.008 | 0.013 | 0.013 | Purinergic P2Y2 agonist | 0.013 0.004 DBMET00532 | DBMET00532 | |
| 0.022 | 0.027 | 0.054 | Vanilloid 2 agonist | 0.035 0.006 DBMET00531 0.054 0.003 DBMET00532 0.036 0.005 DBMET00625 0.033 0.007 DBMET00489 | DBMET00532 | |
| 0.021 | 0.03 | 0.094 | Thyroid hormone agonist | 0.094 0.003 DBMET00625 | DBMET00625 | |
| 0.054 | 0.064 | 0.103 | Corticotropin releasing factor 2 receptor antagonist | 0.067 0.032 DBMET00531 0.103 0.006 DBMET00532 0.074 0.023 DBMET00625 | DBMET00532 | |
| 0.028 | 0.038 | 0.053 | Glutamate (mGluR3) agonist | 0.039 0.01 DBMET00531 0.041 0.009 DBMET00532 0.053 0.004 DBMET00625 0.042 0.008 DBMET00489 | DBMET00625 | |
| 0.05 | 0.061 | 0.081 | Cathepsin E inhibitor | 0.081 0.022 DBMET00532 | DBMET00532 | |
| 0.075 | 0.087 | 0.187 | Estrogen-related receptor beta agonist | 0.108 0.017 DBMET00531 0.107 0.018 DBMET00532 0.187 0.003 DBMET00625 0.109 0.016 DBMET00489 | DBMET00625 | |
| 0.018 | 0.031 | 0.022 | Vitamin D receptor antagonist | 0.022 0.014 DBMET00625 | DBMET00625 | |
| 0.039 | 0.053 | 0.095 | Cholesterol esterase inhibitor | 0.074 0.009 DBMET00532 0.095 0.005 DBMET00625 | DBMET00625 | |
| 0.111 | 0.126 | 0.21 | Protein-tyrosine phosphatase inhibitor | 0.21 0.043 DBMET00625 | DBMET00625 | |
| 0.068 | 0.084 | 0.077 | NMDA receptor antagonist | 0.077 0.069 DBMET00625 | DBMET00625 | |
| 0.004 | 0.021 | 0.053 | Thyroid hormone beta agonist | 0.053 0.003 DBMET00625 | DBMET00625 | |
| 0.051 | 0.067 | 0.055 | Lipocortins synthesis agonist | 0.055 0.048 DBMET00532 | DBMET00532 | |
| 0.052 | 0.069 | 0.099 | Ryanodine receptor antagonist | 0.069 0.018 DBMET00531 0.099 0.004 DBMET00532 0.082 0.008 DBMET00625 0.064 0.027 DBMET00489 | DBMET00532 | |
| 0.027 | 0.044 | 0.059 | Retinoid X alpha receptor antagonist | 0.035 0.023 DBMET00531 0.035 0.021 DBMET00532 0.059 0.004 DBMET00625 0.038 0.018 DBMET00489 | DBMET00625 | |
| 0.007 | 0.026 | 0.019 | N-Acetylated alpha-linked acidic dipeptidase inhibitor | 0.019 0.008 DBMET00532 | DBMET00532 | |
| 0.011 | 0.031 | 0.031 | Inosine monophosphate dehydrogenase 2 inhibitor | 0.031 0.007 DBMET00532 | DBMET00532 | |
| 0.016 | 0.036 | 0.038 | Retinoid X beta receptor antagonist | 0.022 0.011 DBMET00531 0.022 0.012 DBMET00532 0.038 0.003 DBMET00625 0.024 0.008 DBMET00489 | DBMET00625 | |
| 0.037 | 0.058 | 0.155 | Protein 50S ribosomal subunit inhibitor | 0.058 0.033 DBMET00532 0.155 0.006 DBMET00489 | DBMET00489 | |
| 0.025 | 0.046 | 0.042 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.042 0.014 DBMET00532 | DBMET00532 | |
| 0.056 | 0.078 | 0.147 | Aminopeptidase I inhibitor | 0.131 0.016 DBMET00531 0.147 0.013 DBMET00532 0.12 0.02 DBMET00625 0.142 0.014 DBMET00489 | DBMET00532 | |
| 0.057 | 0.079 | 0.086 | HIV-1 integrase inhibitor | 0.086 0.034 DBMET00625 | DBMET00625 | |
| 0.032 | 0.056 | 0.078 | Thymidylate synthase inhibitor | 0.078 0.008 DBMET00532 | DBMET00532 | |
| 0.044 | 0.069 | 0.117 | Androgen agonist | 0.058 0.044 DBMET00531 0.093 0.018 DBMET00532 0.095 0.017 DBMET00625 0.117 0.01 DBMET00489 | DBMET00489 | |
| 0.007 | 0.032 | 0.014 | Purine nucleoside phosphorylase inhibitor | 0.014 0.005 DBMET00532 | DBMET00532 | |
| 0.03 | 0.056 | 0.078 | Leukocyte elastase inhibitor | 0.053 0.022 DBMET00532 0.078 0.013 DBMET00625 0.057 0.019 DBMET00489 | DBMET00625 | |
| 0.189 | 0.215 | 0.546 | Histamine release inhibitor | 0.37 0.09 DBMET00531 0.408 0.071 DBMET00532 0.546 0.017 DBMET00625 0.379 0.086 DBMET00489 | DBMET00625 | |
| 0.06 | 0.095 | 0.119 | Interferon agonist | 0.081 0.051 DBMET00531 0.119 0.017 DBMET00532 0.098 0.03 DBMET00625 0.079 0.053 DBMET00489 | DBMET00532 | |
| 0.068 | 0.106 | 0.227 | Transcription factor NF kappa B stimulant | 0.227 0.007 DBMET00532 | DBMET00532 | |
| 0.071 | 0.109 | 0.628 | Hematopoietic | 0.628 0.003 DBMET00532 | DBMET00532 | |
| 0.077 | 0.115 | 0.192 | Chelator | 0.139 0.04 DBMET00532 0.192 0.026 DBMET00625 | DBMET00625 | |
| 0.078 | 0.122 | 0.204 | Nav1.4 sodium channel blocker | 0.204 0.018 DBMET00625 | DBMET00625 | |
| 0.025 | 0.07 | 0.06 | GABA uptake inhibitor | 0.05 0.016 DBMET00531 0.06 0.01 DBMET00532 0.047 0.018 DBMET00625 0.055 0.012 DBMET00489 | DBMET00532 | |
| 0.053 | 0.099 | 0.109 | Calcium antagonist | 0.082 0.062 DBMET00531 0.109 0.042 DBMET00532 0.107 0.043 DBMET00625 | DBMET00532 | |
| 0.067 | 0.112 | 0.111 | Phosphodiesterase I inhibitor | 0.111 0.033 DBMET00532 0.086 0.066 DBMET00625 | DBMET00532 | |
| 0.122 | 0.168 | 0.187 | Ca2+-transporting ATPase inhibitor | 0.187 0.005 DBMET00531 0.187 0.005 DBMET00532 0.186 0.005 DBMET00625 0.187 0.005 DBMET00489 | DBMET00489 | |
| 0.038 | 0.085 | 0.066 | Heparanase inhibitor | 0.05 0.045 DBMET00531 0.066 0.015 DBMET00532 0.052 0.041 DBMET00625 0.051 0.044 DBMET00489 | DBMET00532 | |
| 0.092 | 0.138 | 0.169 | Toll-Like receptor antagonist | 0.169 0.044 DBMET00532 0.132 0.07 DBMET00625 | DBMET00532 | |
| 0.009 | 0.058 | 0.025 | Adenosine kinase inhibitor | 0.025 0.012 DBMET00532 | DBMET00532 | |
| 0.073 | 0.122 | 0.275 | Anesthetic local | 0.275 0.015 DBMET00625 0.197 0.033 DBMET00489 | DBMET00625 | |
| 0.006 | 0.055 | 0.018 | Retinoic acid receptor gamma antagonist | 0.018 0.004 DBMET00625 | DBMET00625 | |
| 0.031 | 0.08 | 0.069 | Farnesyltransferase inhibitor | 0.069 0.016 DBMET00532 | DBMET00532 | |
| 0.047 | 0.097 | 0.19 | Glutamate decarboxylase inhibitor | 0.165 0.011 DBMET00531 0.176 0.009 DBMET00532 0.141 0.015 DBMET00625 0.19 0.008 DBMET00489 | DBMET00489 | |
| 0.005 | 0.055 | 0.023 | Retinoic acid beta receptor antagonist | 0.023 0.004 DBMET00625 | DBMET00625 | |
| 0.035 | 0.088 | 0.087 | Alpha-mannosidase inhibitor | 0.077 0.012 DBMET00531 0.087 0.009 DBMET00532 0.062 0.024 DBMET00625 0.084 0.01 DBMET00489 | DBMET00532 | |
| 0.018 | 0.071 | 0.044 | Thymidine phosphorylase inhibitor | 0.029 0.014 DBMET00531 0.044 0.005 DBMET00532 0.027 0.015 DBMET00489 | DBMET00532 | |
| 0.006 | 0.061 | 0.022 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.018 0.005 DBMET00531 0.022 0.004 DBMET00532 0.013 0.009 DBMET00625 0.015 0.007 DBMET00489 | DBMET00532 | |
| 0.071 | 0.126 | 0.435 | c-Src kinase inhibitor | 0.435 0.005 DBMET00532 | DBMET00532 | |
| 0.011 | 0.071 | 0.031 | Geranylgeranyltransferase inhibitor | 0.031 0.009 DBMET00532 | DBMET00532 | |
| 0.037 | 0.098 | 0.102 | Bombesin 1 receptor agonist | 0.102 0.017 DBMET00625 | DBMET00625 | |
| 0.062 | 0.125 | 0.227 | Creatine kinase inhibitor | 0.2 0.01 DBMET00531 0.227 0.007 DBMET00532 0.225 0.007 DBMET00625 0.214 0.009 DBMET00489 | DBMET00532 | |
| 0.078 | 0.142 | 0.677 | Alpha-N-acetylglucosaminidase inhibitor | 0.619 0.004 DBMET00531 0.583 0.004 DBMET00532 0.427 0.008 DBMET00625 0.677 0.003 DBMET00489 | DBMET00489 | |
| 0.041 | 0.108 | 0.123 | Na+ K+ transporting ATPase inhibitor | 0.1 0.031 DBMET00531 0.111 0.023 DBMET00532 0.102 0.03 DBMET00625 0.123 0.015 DBMET00489 | DBMET00489 | |
| 0.024 | 0.092 | 0.075 | Mannosidase inhibitor | 0.066 0.014 DBMET00531 0.075 0.01 DBMET00532 0.05 0.025 DBMET00625 0.073 0.011 DBMET00489 | DBMET00532 | |
| 0.02 | 0.089 | 0.048 | RNA-directed RNA polymerase inhibitor | 0.048 0.014 DBMET00532 | DBMET00532 | |
| 0.041 | 0.112 | 0.124 | Polo-like kinase-2 inhibitor | 0.124 0.009 DBMET00532 | DBMET00532 | |
| 0.008 | 0.084 | 0.022 | Adenosine A1 receptor agonist | 0.022 0.019 DBMET00532 | DBMET00532 | |
| 0.034 | 0.11 | 0.156 | Carbonic anhydrase V inhibitor | 0.06 0.054 DBMET00531 0.156 0.013 DBMET00532 | DBMET00532 | |
| 0.057 | 0.133 | 0.179 | Alcohol dehydrogenase inhibitor | 0.096 0.057 DBMET00531 0.179 0.015 DBMET00532 0.101 0.051 DBMET00625 0.1 0.052 DBMET00489 | DBMET00532 | |
| 0.094 | 0.171 | 0.355 | Heat shock protein 90 antagonist | 0.355 0.005 DBMET00625 | DBMET00625 | |
| 0.004 | 0.082 | 0.023 | Imidazoline I2 receptor antagonist | 0.023 0.004 DBMET00625 | DBMET00625 | |
| 0.052 | 0.131 | 0.186 | Aminopeptidase B inhibitor | 0.171 0.03 DBMET00531 0.186 0.025 DBMET00532 0.162 0.033 DBMET00625 0.181 0.026 DBMET00489 | DBMET00532 | |
| 0.005 | 0.084 | 0.016 | Aminopeptidase A inhibitor | 0.016 0.014 DBMET00532 | DBMET00532 | |
| 0.007 | 0.087 | 0.025 | Telomerase stimulant | 0.024 0.005 DBMET00531 0.024 0.004 DBMET00532 0.022 0.006 DBMET00625 0.025 0.004 DBMET00489 | DBMET00489 | |
| 0.013 | 0.094 | 0.062 | Nicotinic acid receptor agonist | 0.042 0.019 DBMET00532 0.062 0.011 DBMET00625 | DBMET00625 | |
| 0.024 | 0.107 | 0.051 | Dihydrofolate reductase inhibitor | 0.041 0.038 DBMET00532 0.051 0.017 DBMET00625 | DBMET00625 | |
| 0.02 | 0.105 | 0.058 | Glutamate (mGluR4) agonist | 0.058 0.009 DBMET00532 | DBMET00532 | |
| 0.007 | 0.093 | 0.029 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.029 0.012 DBMET00625 | DBMET00625 | |
| 0.027 | 0.113 | 0.048 | GABA B receptor antagonist | 0.048 0.022 DBMET00532 | DBMET00532 | |
| 0.054 | 0.14 | 0.08 | Histamine H2 receptor antagonist | 0.08 0.066 DBMET00532 | DBMET00532 | |
| 0.01 | 0.097 | 0.04 | HCV NS5B polymerase inhibitor | 0.04 0.014 DBMET00532 | DBMET00532 | |
| 0.064 | 0.159 | 0.109 | AMP-activated protein kinase stimulant | 0.109 0.059 DBMET00532 0.098 0.073 DBMET00625 | DBMET00532 | |
| 0.062 | 0.156 | 0.245 | GABA C receptor rho-1 antagonist | 0.205 0.007 DBMET00531 0.245 0.004 DBMET00532 0.137 0.028 DBMET00625 0.199 0.008 DBMET00489 | DBMET00532 | |
| 0.01 | 0.105 | 0.052 | Urotensin II agonist | 0.052 0.006 DBMET00532 | DBMET00532 | |
| 0.089 | 0.184 | 0.162 | DNA repair enzyme inhibitor | 0.114 0.085 DBMET00531 0.162 0.022 DBMET00532 | DBMET00532 | |
| 0.077 | 0.174 | 0.24 | Cytidine deaminase inhibitor | 0.24 0.032 DBMET00532 | DBMET00532 | |
| 0.017 | 0.114 | 0.034 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.014 DBMET00531 0.034 0.007 DBMET00532 0.028 0.015 DBMET00489 | DBMET00532 | |
| 0.006 | 0.103 | 0.049 | Calcium-sensing receptor antagonist | 0.049 0.005 DBMET00625 | DBMET00625 | |
| 0.023 | 0.121 | 0.099 | Glutamate (mGluR group III) agonist | 0.099 0.01 DBMET00532 | DBMET00532 | |
| 0.036 | 0.139 | 0.124 | Potassium channel intermediate-conductance Ca-activated blocker | 0.066 0.031 DBMET00531 0.124 0.005 DBMET00532 | DBMET00532 | |
| 0.018 | 0.121 | 0.032 | Carboxypeptidase B inhibitor | 0.032 0.024 DBMET00532 0.031 0.029 DBMET00489 | DBMET00532 | |
| 0.016 | 0.12 | 0.073 | NMDA 2A receptor antagonist | 0.073 0.023 DBMET00625 | DBMET00625 | |
| 0.016 | 0.12 | 0.051 | Estrogen-related receptor gamma antagonist | 0.032 0.013 DBMET00531 0.034 0.01 DBMET00532 0.051 0.003 DBMET00625 0.034 0.01 DBMET00489 | DBMET00625 | |
| 0.058 | 0.163 | 0.154 | Lanosterol 14 alpha demethylase inhibitor | 0.119 0.032 DBMET00531 0.154 0.01 DBMET00532 0.14 0.015 DBMET00625 0.111 0.041 DBMET00489 | DBMET00532 | |
| 0.016 | 0.123 | 0.111 | Dopamine D5 agonist | 0.071 0.008 DBMET00531 0.076 0.007 DBMET00532 0.111 0.004 DBMET00625 0.065 0.01 DBMET00489 | DBMET00625 | |
| 0.027 | 0.134 | 0.172 | Aconitate hydratase inhibitor | 0.144 0.004 DBMET00531 0.127 0.005 DBMET00532 0.099 0.009 DBMET00625 0.172 0.004 DBMET00489 | DBMET00489 | |
| 0.038 | 0.145 | 0.124 | Phospholipase D inhibitor | 0.099 0.015 DBMET00531 0.124 0.005 DBMET00532 0.088 0.024 DBMET00625 0.089 0.023 DBMET00489 | DBMET00532 | |
| 0.02 | 0.128 | 0.053 | NMDA receptor subunit 3B antagonist | 0.038 0.037 DBMET00532 0.053 0.023 DBMET00625 | DBMET00625 | |
| 0.025 | 0.134 | 0.058 | Matrix metalloproteinase (membrane-type) inhibitor | 0.058 0.034 DBMET00489 | DBMET00489 | |
| 0.036 | 0.145 | 0.197 | Heat shock protein 90 beta antagonist | 0.197 0.004 DBMET00625 | DBMET00625 | |
| 0.011 | 0.121 | 0.043 | Sodium/glucose cotransporter inhibitor | 0.025 0.018 DBMET00532 0.042 0.007 DBMET00625 0.043 0.006 DBMET00489 | DBMET00489 | |
| 0.033 | 0.144 | 0.163 | Carbonic anhydrase XIII inhibitor | 0.07 0.058 DBMET00531 0.163 0.019 DBMET00532 0.076 0.053 DBMET00625 0.066 0.062 DBMET00489 | DBMET00532 | |
| 0.016 | 0.128 | 0.066 | Phosphorylase inhibitor | 0.066 0.022 DBMET00532 | DBMET00532 | |
| 0.011 | 0.124 | 0.024 | Toll-Like receptor 8 agonist | 0.024 0.008 DBMET00532 | DBMET00532 | |
| 0.185 | 0.298 | 0.415 | Cyclophilin D inhibitor | 0.415 0.083 DBMET00625 | DBMET00625 | |
| 0.009 | 0.125 | 0.086 | Carbonic anhydrase IV inhibitor | 0.086 0.009 DBMET00532 | DBMET00532 | |
| 0.008 | 0.124 | 0.048 | Imidazoline I1 receptor antagonist | 0.019 0.017 DBMET00531 0.021 0.014 DBMET00532 0.048 0.004 DBMET00625 | DBMET00625 | |
| 0.031 | 0.151 | 0.055 | CD45 antagonist | 0.049 0.037 DBMET00532 0.055 0.027 DBMET00625 | DBMET00625 | |
| 0.04 | 0.161 | 0.355 | Monophenol monooxygenase inhibitor | 0.355 0.013 DBMET00625 0.195 0.034 DBMET00489 | DBMET00625 | |
| 0.016 | 0.138 | 0.046 | Glutamate (mGluR3) antagonist | 0.041 0.02 DBMET00531 0.046 0.015 DBMET00532 0.044 0.017 DBMET00625 0.045 0.016 DBMET00489 | DBMET00532 | |
| 0.002 | 0.126 | 0.01 | Thromboxane agonist | 0.01 0.008 DBMET00625 | DBMET00625 | |
| 0.008 | 0.137 | 0.02 | 5-Alpha-reductase 2 inhibitor | 0.02 0.013 DBMET00625 | DBMET00625 | |
| 0.01 | 0.139 | 0.107 | Estrogen agonist | 0.107 0.016 DBMET00625 | DBMET00625 | |
| 0.144 | 0.274 | 0.414 | Tyrosine 3 hydroxylase inhibitor | 0.372 0.012 DBMET00531 0.367 0.013 DBMET00532 0.414 0.007 DBMET00625 0.372 0.012 DBMET00489 | DBMET00625 | |
| 0.027 | 0.158 | 0.082 | Toll-Like receptor 7 antagonist | 0.082 0.036 DBMET00625 | DBMET00625 | |
| 0.086 | 0.217 | 0.27 | Nitric oxide antagonist | 0.27 0.047 DBMET00625 0.221 0.06 DBMET00489 | DBMET00625 | |
| 0.003 | 0.135 | 0.021 | Ileal bile acid transport inhibitor | 0.021 0.008 DBMET00625 | DBMET00625 | |
| 0.012 | 0.144 | 0.042 | NMDA receptor subunit 3A antagonist | 0.042 0.024 DBMET00625 | DBMET00625 | |
| 0.033 | 0.165 | 0.094 | Cathepsin G inhibitor | 0.078 0.046 DBMET00532 0.094 0.036 DBMET00625 | DBMET00625 | |
| 0.008 | 0.14 | 0.055 | Sodium/glucose cotransporter 2 inhibitor | 0.027 0.017 DBMET00532 0.048 0.007 DBMET00625 0.055 0.005 DBMET00489 | DBMET00489 | |
| 0.101 | 0.236 | 0.898 | Succinate dehydrogenase inhibitor | 0.303 0.01 DBMET00531 0.286 0.013 DBMET00532 0.287 0.013 DBMET00625 0.898 0.002 DBMET00489 | DBMET00489 | |
| 0.019 | 0.155 | 0.048 | Sphingosine kinase 1 inhibitor | 0.048 0.019 DBMET00532 0.048 0.018 DBMET00625 | DBMET00625 | |
| 0.063 | 0.202 | 0.307 | Cyclooxygenase inhibitor | 0.307 0.016 DBMET00625 | DBMET00625 | |
| 0.007 | 0.147 | 0.031 | Estrogen-related receptor gamma agonist | 0.031 0.004 DBMET00625 | DBMET00625 | |
| 0.024 | 0.166 | 0.053 | HCV NS3/NS4A protease inhibitor | 0.053 0.028 DBMET00532 | DBMET00532 | |
| 0.016 | 0.158 | 0.07 | Adenosine deaminase inhibitor | 0.054 0.026 DBMET00531 0.07 0.014 DBMET00532 0.058 0.023 DBMET00489 | DBMET00532 | |
| 0.01 | 0.153 | 0.027 | 1,3-Beta-glucan synthase inhibitor | 0.027 0.023 DBMET00532 | DBMET00532 | |
| 0.02 | 0.169 | 0.068 | Elastase inhibitor | 0.05 0.043 DBMET00625 0.068 0.023 DBMET00489 | DBMET00489 | |
| 0.087 | 0.237 | 0.157 | P-glycoprotein inhibitor | 0.157 0.107 DBMET00625 | DBMET00625 | |
| 0.089 | 0.241 | 0.311 | Interferon gamma antagonist | 0.171 0.056 DBMET00531 0.171 0.057 DBMET00532 0.311 0.018 DBMET00625 0.175 0.053 DBMET00489 | DBMET00625 | |
| 0.008 | 0.16 | 0.139 | 5-Alpha-reductase inhibitor | 0.139 0.007 DBMET00531 0.062 0.015 DBMET00625 | DBMET00531 | |
| 0.009 | 0.161 | 0.04 | Nicotinic acid receptor 2 antagonist | 0.034 0.009 DBMET00531 0.032 0.01 DBMET00532 0.04 0.005 DBMET00625 0.035 0.008 DBMET00489 | DBMET00625 | |
| 0.009 | 0.163 | 0.061 | TRPM8 blocker | 0.061 0.011 DBMET00625 | DBMET00625 | |
| 0.01 | 0.164 | 0.035 | Catechol O-methyltransferase inhibitor | 0.035 0.019 DBMET00625 | DBMET00625 | |
| 0.006 | 0.161 | 0.016 | Vitamin D receptor agonist | 0.016 0.013 DBMET00625 | DBMET00625 | |
| 0.105 | 0.261 | 0.287 | Cyclic AMP phosphodiesterase inhibitor | 0.17 0.122 DBMET00531 0.287 0.047 DBMET00532 0.256 0.061 DBMET00625 | DBMET00532 | |
| 0.008 | 0.167 | 0.033 | Peroxisome proliferator-activated receptor delta agonist | 0.033 0.023 DBMET00625 | DBMET00625 | |
| 0.029 | 0.189 | 0.107 | ZAP-70 protein tyrosine kinase inhibitor | 0.107 0.011 DBMET00532 | DBMET00532 | |
| 0.007 | 0.167 | 0.024 | Alpha 2b adrenoreceptor agonist | 0.024 0.007 DBMET00625 | DBMET00625 | |
| 0.008 | 0.169 | 0.03 | Protease (Human cytomegalovirus) inhibitor | 0.021 0.017 DBMET00531 0.023 0.014 DBMET00532 0.03 0.008 DBMET00625 | DBMET00625 | |
| 0.012 | 0.175 | 0.042 | Estrogen-related receptor alpha antagonist | 0.042 0.017 DBMET00625 | DBMET00625 | |
| 0.008 | 0.172 | 0.024 | Neuraminidase (Influenza B) inhibitor | 0.023 0.011 DBMET00531 0.023 0.011 DBMET00532 0.024 0.009 DBMET00625 0.024 0.009 DBMET00489 | DBMET00489 | |
| 0.012 | 0.179 | 0.064 | Oxytocin agonist | 0.052 0.022 DBMET00531 0.054 0.021 DBMET00532 0.064 0.014 DBMET00625 0.046 0.027 DBMET00489 | DBMET00625 | |
| 0.135 | 0.303 | 0.268 | 5 Hydroxytryptamine 3E antagonist | 0.262 0.012 DBMET00531 0.268 0.01 DBMET00532 0.204 0.056 DBMET00625 0.215 0.042 DBMET00489 | DBMET00532 | |
| 0.008 | 0.179 | 0.025 | Prostaglandin F2 alpha agonist | 0.024 0.014 DBMET00531 0.024 0.014 DBMET00532 0.025 0.013 DBMET00625 0.025 0.012 DBMET00489 | DBMET00489 | |
| 0.043 | 0.216 | 0.552 | GABA C receptor agonist | 0.497 0.004 DBMET00531 0.466 0.004 DBMET00532 0.275 0.011 DBMET00625 0.552 0.003 DBMET00489 | DBMET00489 | |
| 0.011 | 0.185 | 0.036 | Bombesin 1 receptor antagonist | 0.036 0.026 DBMET00625 | DBMET00625 | |
| 0.025 | 0.199 | 0.074 | Sphingosine kinase inhibitor | 0.071 0.024 DBMET00532 0.074 0.02 DBMET00625 0.054 0.051 DBMET00489 | DBMET00625 | |
| 0.013 | 0.188 | 0.095 | Potassium channel Kv1.3 blocker | 0.095 0.009 DBMET00625 | DBMET00625 | |
| 0.009 | 0.185 | 0.057 | Estradiol 17 beta-dehydrogenase inhibitor | 0.057 0.021 DBMET00625 | DBMET00625 | |
| 0.016 | 0.195 | 0.045 | AMPA 4 receptor antagonist | 0.041 0.025 DBMET00532 0.045 0.02 DBMET00625 0.037 0.032 DBMET00489 | DBMET00625 | |
| 0.022 | 0.204 | 0.056 | Glutamate (mGluR4) antagonist | 0.046 0.025 DBMET00531 0.056 0.016 DBMET00532 0.047 0.025 DBMET00625 0.047 0.024 DBMET00489 | DBMET00532 | |
| 0.047 | 0.23 | 0.438 | Cyclooxygenase 1 inhibitor | 0.438 0.005 DBMET00625 | DBMET00625 | |
| 0.009 | 0.193 | 0.055 | Cholesterol ester transfer protein antagonist | 0.055 0.005 DBMET00625 | DBMET00625 | |
| 0.014 | 0.198 | 0.044 | Ceramide glucosyltransferase inhibitor | 0.033 0.029 DBMET00531 0.044 0.012 DBMET00532 0.034 0.027 DBMET00489 | DBMET00532 | |
| 0.017 | 0.202 | 0.088 | GABA receptor antagonist | 0.088 0.019 DBMET00625 | DBMET00625 | |
| 0.008 | 0.193 | 0.02 | Caspase 8 inhibitor | 0.02 0.013 DBMET00625 | DBMET00625 | |
| 0.124 | 0.311 | 0.279 | Nitric-oxide synthase stimulant | 0.279 0.018 DBMET00531 0.274 0.019 DBMET00532 0.263 0.024 DBMET00625 0.264 0.024 DBMET00489 | DBMET00531 | |
| 0.01 | 0.198 | 0.156 | Carbonic anhydrase VB inhibitor | 0.062 0.033 DBMET00531 0.156 0.008 DBMET00532 0.054 0.04 DBMET00489 | DBMET00532 | |
| 0.141 | 0.33 | 0.434 | 5 Hydroxytryptamine uptake stimulant | 0.402 0.014 DBMET00531 0.4 0.014 DBMET00532 0.434 0.009 DBMET00625 0.362 0.022 DBMET00489 | DBMET00625 | |
| 0.017 | 0.207 | 0.035 | Antibiotic Aminoglycoside-like | 0.035 0.028 DBMET00532 | DBMET00532 | |
| 0.02 | 0.21 | 0.074 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.067 0.005 DBMET00531 0.065 0.005 DBMET00532 0.068 0.005 DBMET00625 0.074 0.004 DBMET00489 | DBMET00489 | |
| 0.016 | 0.206 | 0.082 | Antineoplastic antibiotic | 0.082 0.056 DBMET00625 | DBMET00625 | |
| 0.02 | 0.213 | 0.063 | Matrix metalloproteinase inhibitor | 0.063 0.05 DBMET00489 | DBMET00489 | |
| 0.006 | 0.202 | 0.034 | Lysine carboxypeptidase inhibitor | 0.03 0.016 DBMET00531 0.029 0.017 DBMET00532 0.028 0.017 DBMET00625 0.034 0.013 DBMET00489 | DBMET00489 | |
| 0.016 | 0.211 | 0.915 | Alcohol oxidase inhibitor | 0.915 0.002 DBMET00531 0.233 0.005 DBMET00532 0.237 0.005 DBMET00625 0.441 0.004 DBMET00489 | DBMET00531 | |
| 0.053 | 0.249 | 0.122 | Toll-Like receptor 3 antagonist | 0.122 0.028 DBMET00625 | DBMET00625 | |
| 0.002 | 0.199 | 0.031 | Peroxisome proliferator-activated receptor alpha antagonist | 0.031 0.011 DBMET00625 | DBMET00625 | |
| 0.075 | 0.272 | 0.137 | Insulin secretagoues | 0.136 0.09 DBMET00532 0.137 0.088 DBMET00625 | DBMET00625 | |
| 0.014 | 0.211 | 0.063 | Histamine H2 receptor agonist | 0.063 0.013 DBMET00531 0.063 0.013 DBMET00532 0.045 0.027 DBMET00625 0.039 0.036 DBMET00489 | DBMET00532 | |
| 0.009 | 0.207 | 0.052 | Peroxisome proliferator-activated receptor alpha agonist | 0.052 0.031 DBMET00625 | DBMET00625 | |
| 0.082 | 0.282 | 0.192 | Pregnane X receptor agonist | 0.142 0.069 DBMET00531 0.151 0.051 DBMET00532 0.192 0.013 DBMET00625 0.13 0.101 DBMET00489 | DBMET00625 | |
| 0.006 | 0.207 | 0.025 | Isoleucine-tRNA ligase inhibitor | 0.024 0.013 DBMET00531 0.024 0.012 DBMET00532 0.025 0.011 DBMET00625 0.023 0.015 DBMET00489 | DBMET00625 | |
| 0.003 | 0.204 | 0.033 | Carbonic anhydrase VIII inhibitor | 0.033 0.004 DBMET00531 0.032 0.004 DBMET00532 0.03 0.004 DBMET00489 | DBMET00531 | |
| 0.003 | 0.204 | 0.033 | Carbonic anhydrase X inhibitor | 0.033 0.004 DBMET00531 0.032 0.004 DBMET00532 0.03 0.004 DBMET00489 | DBMET00531 | |
| 0.021 | 0.223 | 0.107 | Carbonic anhydrase VA inhibitor | 0.066 0.051 DBMET00531 0.107 0.022 DBMET00532 | DBMET00532 | |
| 0.028 | 0.23 | 0.071 | Metalloproteinase-9 inhibitor | 0.071 0.054 DBMET00489 | DBMET00489 | |
| 0.037 | 0.241 | 0.222 | Prolactin inhibitor | 0.145 0.024 DBMET00531 0.148 0.023 DBMET00532 0.222 0.006 DBMET00625 0.133 0.03 DBMET00489 | DBMET00625 | |
| 0.004 | 0.208 | 0.032 | Nicotinic acid receptor 1 antagonist | 0.019 0.01 DBMET00531 0.019 0.01 DBMET00532 0.032 0.004 DBMET00625 0.02 0.009 DBMET00489 | DBMET00625 | |
| 0.035 | 0.241 | 0.097 | Peroxisome proliferator-activated receptor gamma antagonist | 0.097 0.017 DBMET00625 | DBMET00625 | |
| 0.047 | 0.254 | 0.132 | Granulocyte macrophage colony stimulating factor agonist | 0.132 0.01 DBMET00531 0.13 0.011 DBMET00532 0.128 0.011 DBMET00625 0.122 0.015 DBMET00489 | DBMET00531 | |
| 0.014 | 0.223 | 0.037 | Melatonin receptor 1A agonist | 0.033 0.024 DBMET00531 0.033 0.025 DBMET00532 0.037 0.017 DBMET00625 | DBMET00625 | |
| 0.029 | 0.239 | 0.149 | Topoisomerase I inhibitor | 0.149 0.041 DBMET00489 | DBMET00489 | |
| 0.01 | 0.222 | 0.07 | Aromatase inhibitor | 0.07 0.034 DBMET00625 0.068 0.036 DBMET00489 | DBMET00625 | |
| 0.001 | 0.215 | 0.008 | DNA topoisomerase III inhibitor | 0.008 0.004 DBMET00531 0.008 0.004 DBMET00532 0.007 0.005 DBMET00489 | DBMET00532 | |
| 0.009 | 0.224 | 0.051 | ATP citrate lysase inhibitor | 0.029 0.026 DBMET00531 0.029 0.027 DBMET00532 0.051 0.007 DBMET00625 0.032 0.022 DBMET00489 | DBMET00625 | |
| 0.019 | 0.234 | 0.056 | Leukotriene B4 antagonist | 0.056 0.032 DBMET00625 | DBMET00625 | |
| 0.064 | 0.28 | 0.385 | Heat shock protein 90 alpha antagonist | 0.385 0.006 DBMET00625 | DBMET00625 | |
| 0.025 | 0.244 | 0.089 | Dihydroorotate oxidase inhibitor | 0.074 0.014 DBMET00531 0.072 0.016 DBMET00532 0.089 0.007 DBMET00625 0.08 0.011 DBMET00489 | DBMET00625 | |
| 0.047 | 0.268 | 0.259 | Src kinase inhibitor | 0.259 0.034 DBMET00532 | DBMET00532 | |
| 0.011 | 0.232 | 0.046 | Toll-Like receptor 2 agonist | 0.038 0.031 DBMET00531 0.046 0.025 DBMET00532 0.038 0.031 DBMET00489 | DBMET00532 | |
| 0.019 | 0.241 | 0.073 | Cytokine production stimulant | 0.051 0.027 DBMET00531 0.073 0.006 DBMET00532 0.046 0.042 DBMET00625 | DBMET00532 | |
| 0.006 | 0.23 | 0.022 | Antibiotic Anthracycline-like | 0.021 0.01 DBMET00531 0.021 0.009 DBMET00532 0.022 0.008 DBMET00625 0.021 0.01 DBMET00489 | DBMET00625 | |
| 0.1 | 0.325 | 0.532 | 5 Hydroxytryptamine release stimulant | 0.49 0.029 DBMET00531 0.508 0.026 DBMET00532 0.532 0.022 DBMET00625 0.428 0.04 DBMET00489 | DBMET00625 | |
| 0.003 | 0.23 | 0.013 | Human herpes virus 5 capsid protein P40 inhibitor | 0.013 0.009 DBMET00625 | DBMET00625 | |
| 0.014 | 0.243 | 0.064 | Peroxisome proliferator-activated receptor gamma agonist | 0.064 0.055 DBMET00625 | DBMET00625 | |
| 0.068 | 0.296 | 0.233 | DNA methylase inhibitor | 0.233 0.058 DBMET00532 0.233 0.058 DBMET00625 | DBMET00625 | |
| 0.009 | 0.24 | 0.03 | Calcitonin receptor agonist | 0.029 0.028 DBMET00531 0.03 0.027 DBMET00532 0.029 0.028 DBMET00625 | DBMET00532 | |
| 0.084 | 0.314 | 0.242 | ATPase inhibitor | 0.159 0.087 DBMET00531 0.171 0.069 DBMET00532 0.242 0.015 DBMET00625 0.142 0.115 DBMET00489 | DBMET00625 | |
| 0.019 | 0.249 | 0.068 | Kainate receptor agonist | 0.062 0.006 DBMET00531 0.06 0.007 DBMET00532 0.054 0.011 DBMET00625 0.068 0.005 DBMET00489 | DBMET00489 | |
| 0.003 | 0.234 | 0.02 | Thromboxane A2 agonist | 0.019 0.007 DBMET00531 0.019 0.007 DBMET00532 0.02 0.006 DBMET00489 | DBMET00489 | |
| 0.003 | 0.236 | 0.031 | Prostaglandin H2 antagonist | 0.031 0.012 DBMET00625 | DBMET00625 | |
| 0.017 | 0.255 | 0.427 | Catalase inhibitor | 0.35 0.005 DBMET00531 0.162 0.023 DBMET00532 0.128 0.031 DBMET00625 0.427 0.003 DBMET00489 | DBMET00489 | |
| 0.049 | 0.288 | 0.119 | Phosphodiesterase 6D inhibitor | 0.089 0.077 DBMET00531 0.119 0.026 DBMET00532 0.101 0.049 DBMET00625 | DBMET00532 | |
| 0.011 | 0.25 | 0.076 | Neutrophil collagenase inhibitor | 0.076 0.035 DBMET00489 | DBMET00489 | |
| 0.026 | 0.267 | 0.104 | Glutamate (mGluR7) antagonist | 0.104 0.009 DBMET00531 0.102 0.01 DBMET00532 0.09 0.017 DBMET00625 0.098 0.012 DBMET00489 | DBMET00531 | |
| 0.005 | 0.248 | 0.046 | Free fatty acid receptor 1 antagonist | 0.031 0.027 DBMET00531 0.031 0.028 DBMET00532 0.046 0.011 DBMET00625 0.033 0.024 DBMET00489 | DBMET00625 | |
| 0.04 | 0.284 | 0.1 | Calcium channel P-type blocker | 0.068 0.033 DBMET00531 0.07 0.028 DBMET00532 0.1 0.005 DBMET00625 0.063 0.047 DBMET00489 | DBMET00625 | |
| 0.034 | 0.278 | 0.392 | Ferrochelatase inhibitor | 0.378 0.004 DBMET00531 0.356 0.004 DBMET00532 0.232 0.016 DBMET00625 0.392 0.004 DBMET00489 | DBMET00489 | |
| 0.013 | 0.26 | 0.035 | Hedgehog signaling activator | 0.033 0.009 DBMET00531 0.034 0.008 DBMET00532 0.035 0.007 DBMET00625 0.032 0.009 DBMET00489 | DBMET00625 | |
| 0.051 | 0.298 | 0.147 | Acetylcholine M1 receptor antagonist | 0.147 0.077 DBMET00532 | DBMET00532 | |
| 0.007 | 0.255 | 0.028 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.023 0.01 DBMET00531 0.022 0.011 DBMET00532 0.028 0.005 DBMET00625 0.021 0.013 DBMET00489 | DBMET00625 | |
| 0.004 | 0.253 | 0.026 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.026 0.02 DBMET00532 | DBMET00532 | |
| 0.017 | 0.266 | 0.049 | Adenosine uptake inhibitor | 0.034 0.026 DBMET00531 0.049 0.005 DBMET00532 | DBMET00532 | |
| 0.009 | 0.261 | 0.08 | NMDA 2C receptor antagonist | 0.062 0.043 DBMET00532 0.08 0.025 DBMET00625 | DBMET00625 | |
| 0.115 | 0.373 | 0.592 | GABA C receptor rho-3 antagonist | 0.592 0.008 DBMET00531 0.587 0.009 DBMET00532 0.52 0.021 DBMET00625 0.528 0.019 DBMET00489 | DBMET00531 | |
| 0.013 | 0.276 | 0.056 | Histamine H1 receptor agonist | 0.054 0.013 DBMET00531 0.056 0.012 DBMET00532 0.045 0.028 DBMET00625 | DBMET00532 | |
| 0.051 | 0.316 | 0.162 | Glutamate release inhibitor | 0.124 0.019 DBMET00531 0.125 0.019 DBMET00532 0.162 0.008 DBMET00625 0.111 0.029 DBMET00489 | DBMET00625 | |
| 0.006 | 0.272 | 0.04 | Carnitine palmitoyltransferase 1 inhibitor | 0.04 0.015 DBMET00532 | DBMET00532 | |
| 0.046 | 0.312 | 0.24 | Amyloid beta aggregation inhibitor | 0.24 0.061 DBMET00625 | DBMET00625 | |
| 0.023 | 0.29 | 0.084 | Pregnane X receptor antagonist | 0.073 0.011 DBMET00531 0.073 0.011 DBMET00532 0.084 0.005 DBMET00625 0.069 0.016 DBMET00489 | DBMET00625 | |
| 0.008 | 0.275 | 0.044 | Purinergic P2Y15 antagonist | 0.044 0.005 DBMET00531 0.044 0.005 DBMET00532 0.031 0.016 DBMET00625 0.042 0.006 DBMET00489 | DBMET00532 | |
| 0.019 | 0.287 | 0.07 | Squalene epoxidase inhibitor | 0.056 0.025 DBMET00531 0.059 0.021 DBMET00532 0.07 0.014 DBMET00625 0.047 0.041 DBMET00489 | DBMET00625 | |
| 0.104 | 0.376 | 0.411 | Sodium/bile acid cotransporter inhibitor | 0.411 0.014 DBMET00625 | DBMET00625 | |
| 0.006 | 0.281 | 0.039 | Liver X receptor beta agonist | 0.039 0.016 DBMET00625 | DBMET00625 | |
| 0.005 | 0.281 | 0.04 | Carnitine palmitoyltransferase inhibitor | 0.04 0.016 DBMET00532 | DBMET00532 | |
| 0.003 | 0.283 | 0.053 | Estrogen receptor beta agonist | 0.053 0.019 DBMET00625 | DBMET00625 | |
| 0.048 | 0.328 | 0.561 | Peroxidase inhibitor | 0.456 0.014 DBMET00531 0.441 0.015 DBMET00532 0.561 0.005 DBMET00625 0.476 0.012 DBMET00489 | DBMET00625 | |
| 0.02 | 0.303 | 0.086 | NMDA receptor agonist | 0.074 0.033 DBMET00531 0.086 0.025 DBMET00532 0.068 0.038 DBMET00625 0.084 0.027 DBMET00489 | DBMET00532 | |
| 0.011 | 0.299 | 0.094 | NMDA receptor glycine site agonist | 0.08 0.028 DBMET00531 0.094 0.02 DBMET00532 0.056 0.051 DBMET00625 0.085 0.025 DBMET00489 | DBMET00532 | |
| 0.037 | 0.325 | 0.135 | Proteasome inhibitor | 0.135 0.055 DBMET00625 | DBMET00625 | |
| 0.008 | 0.296 | 0.037 | ICAM 1 antagonist | 0.037 0.005 DBMET00625 | DBMET00625 | |
| 0.049 | 0.339 | 0.208 | Insulin sensitizer | 0.151 0.132 DBMET00531 0.16 0.12 DBMET00532 0.208 0.065 DBMET00625 0.156 0.125 DBMET00489 | DBMET00625 | |
| 0.004 | 0.296 | 0.068 | Urate transporter 1 inhibitor | 0.068 0.011 DBMET00625 | DBMET00625 | |
| 0.031 | 0.323 | 0.219 | HIV-1 integrase (Overall Integration) inhibitor | 0.139 0.03 DBMET00531 0.136 0.031 DBMET00532 0.219 0.008 DBMET00625 0.148 0.026 DBMET00489 | DBMET00625 | |
| 0.002 | 0.295 | 0.014 | NMDA receptor phencyclidine site antagonist | 0.014 0.013 DBMET00625 | DBMET00625 | |
| 0.048 | 0.347 | 0.106 | Interleukin 12 antagonist | 0.106 0.044 DBMET00625 | DBMET00625 | |
| 0.006 | 0.307 | 0.03 | Glucocorticoid antagonist | 0.03 0.024 DBMET00625 | DBMET00625 | |
| 0.041 | 0.343 | 0.183 | ABCA1 expression enhancer | 0.183 0.011 DBMET00625 | DBMET00625 | |
| 0.005 | 0.307 | 0.104 | Carbonic anhydrase inhibitor | 0.104 0.026 DBMET00532 | DBMET00532 | |
| 0.028 | 0.331 | 0.231 | Cystathionine beta-synthase inhibitor | 0.208 0.023 DBMET00531 0.194 0.026 DBMET00532 0.231 0.018 DBMET00625 0.224 0.019 DBMET00489 | DBMET00625 | |
| 0.001 | 0.308 | 0.006 | CC chemokine 6 receptor agonist | 0.006 0.005 DBMET00532 | DBMET00532 | |
| 0.003 | 0.311 | 0.018 | Complement factor D inhibitor | 0.018 0.012 DBMET00532 | DBMET00532 | |
| 0.021 | 0.328 | 0.118 | GABA aminotransferase inhibitor | 0.1 0.027 DBMET00531 0.095 0.031 DBMET00532 0.118 0.017 DBMET00625 0.105 0.024 DBMET00489 | DBMET00625 | |
| 0.004 | 0.312 | 0.039 | Glutamate (mGluR1a) agonist | 0.039 0.006 DBMET00531 0.036 0.007 DBMET00532 0.025 0.012 DBMET00625 0.035 0.007 DBMET00489 | DBMET00531 | |
| 0.017 | 0.326 | 0.041 | Leukotriene C4 antagonist | 0.041 0.022 DBMET00625 | DBMET00625 | |
| 0.015 | 0.325 | 0.167 | Phenylalanine 4-hydroxylase inhibitor | 0.141 0.013 DBMET00531 0.132 0.015 DBMET00532 0.157 0.011 DBMET00625 0.167 0.01 DBMET00489 | DBMET00489 | |
| 0.017 | 0.328 | 0.066 | 5 Hydroxytryptamine 7 agonist | 0.066 0.024 DBMET00625 | DBMET00625 | |
| 0.029 | 0.34 | 0.079 | Phosphodiesterase VI inhibitor | 0.079 0.044 DBMET00532 | DBMET00532 | |
| 0.035 | 0.346 | 0.273 | Amylase inhibitor | 0.16 0.059 DBMET00531 0.202 0.044 DBMET00532 0.273 0.023 DBMET00625 0.174 0.054 DBMET00489 | DBMET00625 | |
| 0.077 | 0.39 | 0.218 | Histone acetyltransferase inhibitor | 0.198 0.072 DBMET00532 0.218 0.046 DBMET00625 | DBMET00625 | |
| 0.021 | 0.334 | 0.069 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.069 0.029 DBMET00532 0.06 0.044 DBMET00625 | DBMET00532 | |
| 0.001 | 0.317 | 0.012 | Angiotensin AT2 receptor agonist | 0.012 0.006 DBMET00489 | DBMET00489 | |
| 0.024 | 0.34 | 0.131 | Urease inhibitor | 0.088 0.081 DBMET00531 0.104 0.062 DBMET00532 0.131 0.035 DBMET00625 | DBMET00625 | |
| 0.006 | 0.323 | 0.039 | Angiotensin AT1 receptor antagonist | 0.039 0.036 DBMET00532 | DBMET00532 | |
| 0.025 | 0.345 | 0.116 | ATPase (Vacuolar H+) inhibitor | 0.116 0.023 DBMET00625 | DBMET00625 | |
| 0.011 | 0.331 | 0.095 | Leukotriene antagonist | 0.095 0.024 DBMET00625 | DBMET00625 | |
| 0.002 | 0.323 | 0.012 | Integrin beta2 antagonist | 0.012 0.009 DBMET00625 | DBMET00625 | |
| 0.025 | 0.349 | 0.063 | Leukotriene C antagonist | 0.055 0.045 DBMET00531 0.055 0.045 DBMET00532 0.063 0.023 DBMET00625 0.055 0.042 DBMET00489 | DBMET00625 | |
| 0.003 | 0.327 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.011 DBMET00532 0.018 0.011 DBMET00625 | DBMET00625 | |
| 0.071 | 0.401 | 0.236 | Lipocortins synthesis antagonist | 0.236 0.038 DBMET00625 | DBMET00625 | |
| 0.001 | 0.332 | 0.016 | Carbonic anhydrase XI inhibitor | 0.016 0.005 DBMET00531 0.015 0.006 DBMET00532 0.013 0.009 DBMET00489 | DBMET00531 | |
| 0.007 | 0.339 | 0.049 | Glutamate (mGluR5) agonist | 0.049 0.027 DBMET00532 | DBMET00532 | |
| 0.004 | 0.341 | 0.036 | Kainate receptor 2 antagonist | 0.036 0.025 DBMET00532 | DBMET00532 | |
| 0.019 | 0.36 | 0.074 | Protease 3C (Human rhinovirus) inhibitor | 0.074 0.033 DBMET00531 0.073 0.033 DBMET00532 0.073 0.033 DBMET00625 | DBMET00531 | |
| 0.009 | 0.351 | 0.043 | Carbonic anhydrase XIV inhibitor | 0.043 0.042 DBMET00532 | DBMET00532 | |
| 0.039 | 0.381 | 0.277 | NADPH oxidase inhibitor | 0.126 0.076 DBMET00532 0.277 0.016 DBMET00625 | DBMET00625 | |
| 0.008 | 0.351 | 0.036 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.036 0.027 DBMET00625 | DBMET00625 | |
| 0.03 | 0.374 | 0.129 | Estrogen receptor alpha antagonist | 0.129 0.016 DBMET00625 | DBMET00625 | |
| 0.068 | 0.414 | 0.469 | Superoxide dismutase inhibitor | 0.342 0.038 DBMET00531 0.32 0.044 DBMET00532 0.469 0.016 DBMET00625 0.337 0.04 DBMET00489 | DBMET00625 | |
| 0.029 | 0.376 | 0.065 | Immunoglobulin Fc receptor antagonist | 0.064 0.017 DBMET00531 0.064 0.017 DBMET00532 0.065 0.016 DBMET00625 0.06 0.024 DBMET00489 | DBMET00625 | |
| 0.03 | 0.384 | 0.253 | Xanthine oxidase inhibitor | 0.253 0.012 DBMET00531 0.092 0.068 DBMET00532 | DBMET00531 | |
| 0.05 | 0.406 | 0.253 | GABA C receptor rho-2 antagonist | 0.253 0.011 DBMET00531 0.248 0.012 DBMET00532 0.198 0.03 DBMET00625 0.228 0.017 DBMET00489 | DBMET00531 | |
| 0.004 | 0.361 | 0.043 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.043 0.014 DBMET00625 | DBMET00625 | |
| 0.038 | 0.395 | 0.16 | Photosensitizer | 0.141 0.037 DBMET00531 0.139 0.038 DBMET00532 0.16 0.026 DBMET00625 0.134 0.042 DBMET00489 | DBMET00625 | |
| 0.01 | 0.368 | 0.051 | Dihydroorotase inhibitor | 0.042 0.035 DBMET00531 0.051 0.023 DBMET00532 0.045 0.03 DBMET00489 | DBMET00532 | |
| 0.03 | 0.396 | 0.123 | Bile acid receptor antagonist | 0.091 0.072 DBMET00531 0.09 0.073 DBMET00532 0.123 0.018 DBMET00625 0.091 0.071 DBMET00489 | DBMET00625 | |
| 0.012 | 0.38 | 0.078 | Adenylate cyclase 1 inhibitor | 0.078 0.009 DBMET00531 0.077 0.009 DBMET00532 0.065 0.014 DBMET00625 0.061 0.017 DBMET00489 | DBMET00531 | |
| 0.02 | 0.391 | 0.083 | Interferon inducer | 0.067 0.039 DBMET00531 0.072 0.032 DBMET00532 0.083 0.021 DBMET00625 0.066 0.041 DBMET00489 | DBMET00625 | |
| 0.02 | 0.391 | 0.183 | Mediator release inhibitor | 0.183 0.018 DBMET00625 | DBMET00625 | |
| 0.009 | 0.381 | 0.047 | Prolyl endopeptidase inhibitor | 0.046 0.043 DBMET00531 0.047 0.041 DBMET00532 | DBMET00532 | |
| 0.043 | 0.417 | 0.617 | Aldehyde oxidase inhibitor | 0.535 0.028 DBMET00531 0.507 0.032 DBMET00532 0.617 0.017 DBMET00625 0.579 0.022 DBMET00489 | DBMET00625 | |
| 0.026 | 0.401 | 0.154 | Neurotrophic factor | 0.154 0.056 DBMET00532 | DBMET00532 | |
| 0.009 | 0.384 | 0.065 | Liver X receptor alpha agonist | 0.065 0.01 DBMET00625 | DBMET00625 | |
| 0.043 | 0.419 | 0.319 | Platelet adhesion inhibitor | 0.319 0.028 DBMET00532 0.132 0.128 DBMET00625 | DBMET00532 | |
| 0.047 | 0.422 | 0.162 | Hemostatic | 0.162 0.055 DBMET00532 0.124 0.106 DBMET00625 | DBMET00532 | |
| 0.038 | 0.414 | 0.19 | Interleukin 1 antagonist | 0.19 0.037 DBMET00625 | DBMET00625 | |
| 0.005 | 0.382 | 0.053 | Liver X receptor beta antagonist | 0.053 0.007 DBMET00625 | DBMET00625 | |
| 0.045 | 0.421 | 0.118 | CC chemokine 5 receptor agonist | 0.095 0.028 DBMET00531 0.096 0.026 DBMET00532 0.118 0.009 DBMET00625 0.083 0.054 DBMET00489 | DBMET00625 | |
| 0.006 | 0.385 | 0.027 | Peptide deformylase inhibitor | 0.027 0.025 DBMET00532 | DBMET00532 | |
| 0.007 | 0.386 | 0.038 | Histone deacetylase 7 inhibitor | 0.038 0.025 DBMET00625 | DBMET00625 | |
| 0.01 | 0.389 | 0.062 | Plasminogen activator inhibitor | 0.062 0.038 DBMET00625 | DBMET00625 | |
| 0.03 | 0.409 | 0.102 | Vanilloid 4 agonist | 0.101 0.016 DBMET00531 0.102 0.015 DBMET00532 0.087 0.03 DBMET00625 0.091 0.025 DBMET00489 | DBMET00532 | |
| 0.013 | 0.393 | 0.114 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.069 0.022 DBMET00531 0.067 0.024 DBMET00532 0.114 0.008 DBMET00625 0.07 0.021 DBMET00489 | DBMET00625 | |
| 0.006 | 0.387 | 0.07 | Alpha 1d adrenoreceptor agonist | 0.062 0.01 DBMET00531 0.07 0.007 DBMET00532 0.067 0.008 DBMET00625 0.044 0.021 DBMET00489 | DBMET00532 | |
| 0.03 | 0.414 | 0.071 | Transcription factor RelA inhibitor | 0.071 0.028 DBMET00531 0.071 0.028 DBMET00532 0.071 0.029 DBMET00625 0.062 0.049 DBMET00489 | DBMET00625 | |
| 0.021 | 0.406 | 0.079 | Beta 3 adrenoreceptor antagonist | 0.079 0.024 DBMET00625 | DBMET00625 | |
| 0.063 | 0.45 | 0.287 | Hypoglycemic | 0.287 0.057 DBMET00625 | DBMET00625 | |
| 0.014 | 0.403 | 0.111 | CYP2A6 inhibitor | 0.111 0.031 DBMET00531 0.108 0.032 DBMET00532 0.081 0.047 DBMET00625 | DBMET00531 | |
| 0.006 | 0.396 | 0.049 | Glutamate (mGluR group I) agonist | 0.049 0.032 DBMET00532 | DBMET00532 | |
| 0.051 | 0.443 | 0.152 | Tumour necrosis factor antagonist | 0.129 0.128 DBMET00532 0.152 0.098 DBMET00625 | DBMET00625 | |
| 0.002 | 0.397 | 0.019 | Cyclin T1 inhibitor | 0.016 0.015 DBMET00531 0.019 0.011 DBMET00532 | DBMET00532 | |
| 0.018 | 0.415 | 0.079 | Potassium channel (Tandem pore domain) blocker | 0.079 0.037 DBMET00531 0.078 0.038 DBMET00532 0.077 0.041 DBMET00625 | DBMET00531 | |
| 0.138 | 0.536 | 0.514 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.514 0.028 DBMET00531 0.512 0.029 DBMET00532 0.402 0.099 DBMET00625 0.469 0.049 DBMET00489 | DBMET00531 | |
| 0.014 | 0.415 | 0.103 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.101 0.013 DBMET00531 0.103 0.012 DBMET00532 0.079 0.039 DBMET00625 0.088 0.024 DBMET00489 | DBMET00532 | |
| 0.014 | 0.414 | 0.063 | Dopamine beta hydroxylase inhibitor | 0.059 0.017 DBMET00531 0.06 0.015 DBMET00532 0.063 0.012 DBMET00625 0.053 0.025 DBMET00489 | DBMET00625 | |
| 0.035 | 0.436 | 0.294 | Nav1.2 sodium channel blocker | 0.294 0.015 DBMET00625 | DBMET00625 | |
| 0.007 | 0.409 | 0.065 | Dihydroorotate dehydrogenase inhibitor | 0.065 0.024 DBMET00625 | DBMET00625 | |
| 0.05 | 0.454 | 0.4 | 12-Lipoxygenase inhibitor | 0.4 0.039 DBMET00625 | DBMET00625 | |
| 0.065 | 0.474 | 0.296 | Gastrin inhibitor | 0.253 0.076 DBMET00531 0.253 0.076 DBMET00532 0.296 0.036 DBMET00625 0.24 0.091 DBMET00489 | DBMET00625 | |
| 0.007 | 0.422 | 0.038 | Delayed rectifier potassium channel blocker | 0.036 0.028 DBMET00531 0.036 0.029 DBMET00532 0.038 0.025 DBMET00625 | DBMET00625 | |
| 0.003 | 0.418 | 0.04 | Nicotinic alpha3beta4 receptor agonist | 0.039 0.011 DBMET00531 0.04 0.01 DBMET00532 | DBMET00532 | |
| 0.036 | 0.453 | 0.249 | Calpain inhibitor | 0.173 0.144 DBMET00532 0.249 0.066 DBMET00625 | DBMET00625 | |
| 0.009 | 0.432 | 0.086 | Maillard reaction inhibitor | 0.086 0.022 DBMET00625 | DBMET00625 | |
| 0.002 | 0.426 | 0.05 | Arginase inhibitor | 0.045 0.018 DBMET00531 0.044 0.019 DBMET00532 0.05 0.015 DBMET00489 | DBMET00489 | |
| 0.029 | 0.453 | 0.102 | mTOR complex 2 inhibitor | 0.098 0.035 DBMET00531 0.102 0.031 DBMET00532 0.1 0.033 DBMET00625 0.087 0.053 DBMET00489 | DBMET00532 | |
| 0.017 | 0.441 | 0.056 | Nicotinic alpha3beta2 receptor antagonist | 0.056 0.032 DBMET00531 0.056 0.032 DBMET00532 0.051 0.04 DBMET00625 | DBMET00532 | |
| 0.013 | 0.44 | 0.045 | Beta adrenoreceptor agonist | 0.043 0.04 DBMET00625 0.045 0.033 DBMET00489 | DBMET00489 | |
| 0.004 | 0.433 | 0.043 | Dihydropteroate synthase inhibitor | 0.043 0.023 DBMET00531 0.043 0.023 DBMET00532 0.035 0.034 DBMET00625 0.04 0.027 DBMET00489 | DBMET00532 | |
| 0.005 | 0.434 | 0.028 | Acid ceramidase inhibitor | 0.028 0.012 DBMET00531 0.027 0.013 DBMET00532 | DBMET00531 | |
| 0.03 | 0.46 | 0.446 | Thioredoxin reductase inhibitor | 0.446 0.002 DBMET00489 | DBMET00489 | |
| 0.005 | 0.434 | 0.03 | LFA antagonist | 0.03 0.016 DBMET00625 | DBMET00625 | |
| 0.022 | 0.452 | 0.103 | Exportin-1 inhibitor | 0.103 0.008 DBMET00531 0.102 0.008 DBMET00532 0.068 0.048 DBMET00625 0.081 0.023 DBMET00489 | DBMET00531 | |
| 0.012 | 0.445 | 0.066 | Carbonic anhydrase stimulant | 0.066 0.035 DBMET00531 0.066 0.035 DBMET00532 0.058 0.043 DBMET00625 0.064 0.037 DBMET00489 | DBMET00532 | |
| 0.004 | 0.437 | 0.014 | Integrin alphaLbeta2 antagonist | 0.014 0.008 DBMET00625 | DBMET00625 | |
| 0.009 | 0.442 | 0.031 | Complement factor 1s inhibitor | 0.03 0.008 DBMET00531 0.031 0.007 DBMET00532 0.024 0.022 DBMET00489 | DBMET00532 | |
| 0.012 | 0.449 | 0.041 | Potassium channel Kv1.1 blocker | 0.041 0.021 DBMET00531 0.04 0.023 DBMET00532 | DBMET00531 | |
| 0.03 | 0.467 | 0.077 | MDM2 inhibitor | 0.069 0.041 DBMET00531 0.071 0.035 DBMET00532 0.077 0.024 DBMET00625 0.067 0.047 DBMET00489 | DBMET00625 | |
| 0.007 | 0.445 | 0.031 | Glutamate (mGluR1) agonist | 0.026 0.014 DBMET00531 0.025 0.015 DBMET00532 0.031 0.009 DBMET00625 0.026 0.014 DBMET00489 | DBMET00625 | |
| 0.018 | 0.458 | 0.048 | Heme oxygenase inhibitor | 0.047 0.018 DBMET00531 0.048 0.017 DBMET00532 0.043 0.029 DBMET00489 | DBMET00532 | |
| 0.006 | 0.447 | 0.083 | GABA A receptor antagonist | 0.083 0.02 DBMET00625 | DBMET00625 | |
| 0.003 | 0.446 | 0.032 | Methionyl aminopeptidase 1 inhibitor | 0.032 0.022 DBMET00532 | DBMET00532 | |
| 0.006 | 0.449 | 0.021 | Factor XIII inhibitor | 0.021 0.014 DBMET00531 0.021 0.015 DBMET00532 | DBMET00532 | |
| 0.008 | 0.453 | 0.07 | 5 Hydroxytryptamine 2A agonist | 0.07 0.037 DBMET00532 | DBMET00532 | |
| 0.006 | 0.452 | 0.061 | Glycine transporter 2 inhibitor | 0.061 0.025 DBMET00625 | DBMET00625 | |
| 0.011 | 0.457 | 0.061 | Epithelial sodium channel blocker | 0.056 0.035 DBMET00531 0.061 0.028 DBMET00532 0.051 0.048 DBMET00625 | DBMET00532 | |
| 0.004 | 0.45 | 0.033 | Epoxide hydrolase 1 inhibitor | 0.033 0.018 DBMET00531 0.031 0.021 DBMET00532 | DBMET00531 | |
| 0.031 | 0.477 | 0.134 | Carbonic anhydrase XV inhibitor | 0.134 0.038 DBMET00531 0.13 0.04 DBMET00532 0.128 0.041 DBMET00625 0.131 0.039 DBMET00489 | DBMET00531 | |
| 0.018 | 0.465 | 0.049 | Bombesin 2 receptor antagonist | 0.046 0.04 DBMET00532 0.049 0.034 DBMET00625 | DBMET00625 | |
| 0.014 | 0.461 | 0.071 | Beta 2 adrenoreceptor agonist | 0.06 0.049 DBMET00532 0.066 0.028 DBMET00625 0.071 0.018 DBMET00489 | DBMET00489 | |
| 0.014 | 0.463 | 0.077 | Botulinum neurotoxin type A inhibitor | 0.077 0.019 DBMET00625 | DBMET00625 | |
| 0.009 | 0.459 | 0.056 | Beta 1 adrenoreceptor antagonist | 0.056 0.039 DBMET00625 | DBMET00625 | |
| 0.01 | 0.461 | 0.056 | Beta 2 adrenoreceptor antagonist | 0.056 0.028 DBMET00625 | DBMET00625 | |
| 0.012 | 0.466 | 0.068 | Aryl hydrocarbon receptor antagonist | 0.059 0.056 DBMET00531 0.058 0.057 DBMET00532 0.068 0.041 DBMET00625 | DBMET00625 | |
| 0.003 | 0.457 | 0.033 | Nicotinic alpha4beta2 receptor agonist | 0.033 0.014 DBMET00531 0.033 0.013 DBMET00532 | DBMET00532 | |
| 0.027 | 0.484 | 0.49 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.49 0.021 DBMET00625 | DBMET00625 | |
| 0.027 | 0.488 | 0.174 | Estrogen antagonist | 0.174 0.017 DBMET00625 | DBMET00625 | |
| 0.007 | 0.468 | 0.066 | Cyclin-dependent kinase 6 inhibitor | 0.066 0.035 DBMET00532 | DBMET00532 | |
| 0.018 | 0.479 | 0.107 | Gastric antisecretory | 0.107 0.057 DBMET00625 | DBMET00625 | |
| 0.016 | 0.478 | 0.056 | Phosphodiesterase 1A inhibitor | 0.056 0.051 DBMET00625 | DBMET00625 | |
| 0.003 | 0.467 | 0.035 | Diamine oxidase inhibitor | 0.034 0.031 DBMET00531 0.035 0.03 DBMET00532 | DBMET00532 | |
| 0.012 | 0.476 | 0.072 | Beta adrenoreceptor antagonist | 0.072 0.035 DBMET00625 | DBMET00625 | |
| 0.006 | 0.474 | 0.094 | Acetylcholine M5 receptor agonist | 0.094 0.023 DBMET00531 0.092 0.025 DBMET00532 | DBMET00531 | |
| 0.047 | 0.515 | 0.145 | MAP kinase 3 inhibitor | 0.125 0.121 DBMET00531 0.145 0.076 DBMET00532 | DBMET00532 | |
| 0.004 | 0.474 | 0.206 | Elastase 2 inhibitor | 0.206 0.001 DBMET00489 | DBMET00489 | |
| 0.004 | 0.474 | 0.206 | Elastase 2A inhibitor | 0.206 0.001 DBMET00489 | DBMET00489 | |
| 0.012 | 0.484 | 0.077 | Cyclin D1 inhibitor | 0.055 0.051 DBMET00531 0.054 0.053 DBMET00532 0.077 0.021 DBMET00625 | DBMET00625 | |
| 0.005 | 0.478 | 0.066 | Thromboxane antagonist | 0.066 0.028 DBMET00625 | DBMET00625 | |
| 0.016 | 0.489 | 0.06 | Histone deacetylase SIRT3 inhibitor | 0.06 0.048 DBMET00531 0.06 0.049 DBMET00532 | DBMET00532 | |
| 0.025 | 0.499 | 0.126 | Carbonic anhydrase III inhibitor | 0.115 0.048 DBMET00531 0.112 0.05 DBMET00532 0.126 0.04 DBMET00625 0.115 0.048 DBMET00489 | DBMET00625 | |
| 0.009 | 0.484 | 0.028 | Glucosylceramidase stimulant | 0.028 0.017 DBMET00531 0.028 0.018 DBMET00532 | DBMET00532 | |
| 0.062 | 0.538 | 0.177 | Papain-like protease (SARS coronavirus) inhibitor | 0.177 0.017 DBMET00625 | DBMET00625 | |
| 0.039 | 0.518 | 0.399 | Thyroid hormone antagonist | 0.399 0.056 DBMET00625 | DBMET00625 | |
| 0.009 | 0.49 | 0.136 | Androgen antagonist | 0.136 0.027 DBMET00625 | DBMET00625 | |
| 0.022 | 0.505 | 0.156 | Cathepsin H inhibitor | 0.156 0.042 DBMET00531 0.154 0.043 DBMET00532 0.133 0.06 DBMET00625 0.135 0.058 DBMET00489 | DBMET00531 | |
| 0.009 | 0.498 | 0.062 | Potassium channel (ATP-sensitive) activator | 0.052 0.027 DBMET00531 0.062 0.014 DBMET00532 | DBMET00532 | |
| 0.01 | 0.501 | 0.065 | Potassium channel (Inward rectifier) activator | 0.055 0.027 DBMET00531 0.065 0.015 DBMET00532 | DBMET00532 | |
| 0.083 | 0.575 | 0.508 | 5 Hydroxytryptamine release inhibitor | 0.464 0.046 DBMET00531 0.453 0.05 DBMET00532 0.508 0.03 DBMET00625 0.46 0.047 DBMET00489 | DBMET00625 | |
| 0.005 | 0.499 | 0.064 | Protein 30S ribosomal subunit inhibitor | 0.064 0.005 DBMET00489 | DBMET00489 | |
| 0.023 | 0.517 | 0.156 | Electrolyte absorption antagonist | 0.156 0.017 DBMET00531 0.155 0.018 DBMET00532 0.12 0.036 DBMET00625 0.154 0.018 DBMET00489 | DBMET00531 | |
| 0.003 | 0.498 | 0.035 | Endothelial nitric-oxide synthase inhibitor | 0.035 0.017 DBMET00625 | DBMET00625 | |
| 0.017 | 0.513 | 0.055 | Phosphodiesterase 1B inhibitor | 0.055 0.049 DBMET00625 | DBMET00625 | |
| 0.019 | 0.516 | 0.109 | Carbonic anhydrase VI inhibitor | 0.084 0.052 DBMET00531 0.082 0.055 DBMET00532 0.109 0.034 DBMET00625 0.082 0.055 DBMET00489 | DBMET00625 | |
| 0.003 | 0.502 | 0.037 | Potassium channel small-conductance Ca-activated activator | 0.034 0.019 DBMET00531 0.037 0.017 DBMET00532 | DBMET00532 | |
| 0.024 | 0.524 | 0.091 | MAP kinase kinase 7 inhibitor | 0.09 0.024 DBMET00531 0.091 0.022 DBMET00532 0.091 0.023 DBMET00625 0.09 0.024 DBMET00489 | DBMET00625 | |
| 0.007 | 0.508 | 0.075 | Collagenase 3 inhibitor | 0.075 0.028 DBMET00489 | DBMET00489 | |
| 0.023 | 0.525 | 0.119 | Antibacterial (Helicobacter pylori) | 0.119 0.082 DBMET00625 | DBMET00625 | |
| 0.003 | 0.506 | 0.013 | Cyclin D2 inhibitor | 0.013 0.01 DBMET00531 0.013 0.01 DBMET00532 | DBMET00532 | |
| 0.004 | 0.512 | 0.063 | Thromboxane A2 antagonist | 0.063 0.026 DBMET00625 | DBMET00625 | |
| 0.005 | 0.514 | 0.054 | Nerve growth factor antagonist | 0.054 0.014 DBMET00531 0.053 0.014 DBMET00532 0.049 0.02 DBMET00489 | DBMET00531 | |
| 0.007 | 0.518 | 0.031 | Cyclophilin A inhibitor | 0.031 0.021 DBMET00625 | DBMET00625 | |
| 0.007 | 0.518 | 0.037 | 5 Hydroxytryptamine 2B agonist | 0.037 0.032 DBMET00532 | DBMET00532 | |
| 0.006 | 0.517 | 0.026 | Integrin alpha2beta1 antagonist | 0.025 0.022 DBMET00531 0.025 0.022 DBMET00532 0.026 0.02 DBMET00489 | DBMET00489 | |
| 0.003 | 0.516 | 0.028 | Glucagon receptor antagonist | 0.028 0.022 DBMET00625 | DBMET00625 | |
| 0.037 | 0.551 | 0.189 | 3C-like protease (Human coronavirus) inhibitor | 0.189 0.059 DBMET00531 0.181 0.064 DBMET00532 0.186 0.06 DBMET00625 0.143 0.114 DBMET00489 | DBMET00531 | |
| 0.003 | 0.518 | 0.038 | CXC chemokine 2 receptor antagonist | 0.038 0.009 DBMET00625 | DBMET00625 | |
| 0.002 | 0.518 | 0.015 | Nicotinic alpha4 receptor agonist | 0.015 0.014 DBMET00532 | DBMET00532 | |
| 0.007 | 0.528 | 0.063 | Thromboxane synthase inhibitor | 0.063 0.024 DBMET00625 | DBMET00625 | |
| 0.053 | 0.577 | 0.198 | Neurotensin receptor agonist | 0.167 0.067 DBMET00531 0.169 0.064 DBMET00532 0.198 0.036 DBMET00625 0.166 0.069 DBMET00489 | DBMET00625 | |
| 0.013 | 0.538 | 0.117 | Macrophage migration inhibitory factor inhibitor | 0.117 0.027 DBMET00625 | DBMET00625 | |
| 0.015 | 0.541 | 0.049 | Topoisomerase II beta inhibitor | 0.048 0.037 DBMET00531 0.047 0.038 DBMET00532 0.049 0.034 DBMET00625 0.045 0.042 DBMET00489 | DBMET00625 | |
| 0.021 | 0.55 | 0.143 | Interleukin 8 antagonist | 0.1 0.097 DBMET00532 0.143 0.039 DBMET00625 | DBMET00625 | |
| 0.003 | 0.532 | 0.167 | Estrone sulfatase inhibitor | 0.167 0.003 DBMET00489 | DBMET00489 | |
| 0.016 | 0.55 | 0.187 | 5 Hydroxytryptamine 3A agonist | 0.187 0.019 DBMET00531 0.186 0.019 DBMET00532 0.114 0.062 DBMET00625 0.123 0.053 DBMET00489 | DBMET00531 | |
| 0.012 | 0.548 | 0.1 | MAP kinase kinase 1 inhibitor | 0.1 0.056 DBMET00532 0.085 0.077 DBMET00625 | DBMET00532 | |
| 0.017 | 0.554 | 0.074 | Phosphodiesterase 1C inhibitor | 0.074 0.024 DBMET00625 | DBMET00625 | |
| 0.012 | 0.556 | 0.072 | 5 Hydroxytryptamine 3 agonist | 0.069 0.037 DBMET00531 0.072 0.034 DBMET00532 | DBMET00532 | |
| 0.012 | 0.555 | 0.083 | Calcium channel L-type blocker | 0.083 0.037 DBMET00625 | DBMET00625 | |
| 0.015 | 0.559 | 0.116 | Interleukin 1 beta converting enzyme inhibitor | 0.085 0.08 DBMET00532 0.116 0.039 DBMET00625 | DBMET00625 | |
| 0.013 | 0.558 | 0.116 | Histamine N-methyltransferase inhibitor | 0.112 0.035 DBMET00531 0.116 0.032 DBMET00532 0.08 0.066 DBMET00625 0.087 0.059 DBMET00489 | DBMET00532 | |
| 0.006 | 0.564 | 0.035 | Integrin alpha2 antagonist | 0.034 0.031 DBMET00531 0.034 0.032 DBMET00532 0.035 0.029 DBMET00489 | DBMET00489 | |
| 0.014 | 0.574 | 0.122 | Caspase 3 inhibitor | 0.102 0.088 DBMET00532 0.122 0.057 DBMET00625 | DBMET00625 | |
| 0.005 | 0.565 | 0.085 | Benzodiazepine agonist | 0.085 0.035 DBMET00489 | DBMET00489 | |
| 0.012 | 0.572 | 0.126 | Falcipain 3 inhibitor | 0.126 0.05 DBMET00531 0.126 0.05 DBMET00532 0.097 0.073 DBMET00625 0.099 0.071 DBMET00489 | DBMET00532 | |
| 0.012 | 0.575 | 0.195 | Aryl hydrocarbon receptor agonist | 0.195 0.105 DBMET00625 | DBMET00625 | |
| 0.011 | 0.574 | 0.056 | Fatty acid synthase inhibitor | 0.056 0.041 DBMET00625 | DBMET00625 | |
| 0.003 | 0.566 | 0.027 | 5 Hydroxytryptamine 6 agonist | 0.027 0.024 DBMET00532 | DBMET00532 | |
| 0.03 | 0.6 | 0.362 | Thyroid hormone beta antagonist | 0.362 0.065 DBMET00625 | DBMET00625 | |
| 0.004 | 0.575 | 0.107 | Prostaglandin-E synthase inhibitor | 0.107 0.024 DBMET00625 | DBMET00625 | |
| 0.015 | 0.59 | 0.14 | Beta glucuronidase inhibitor | 0.14 0.03 DBMET00625 | DBMET00625 | |
| 0.015 | 0.598 | 0.14 | Nav1.6 sodium channel blocker | 0.124 0.089 DBMET00531 0.132 0.078 DBMET00532 0.14 0.067 DBMET00625 | DBMET00625 | |
| 0.019 | 0.603 | 0.129 | Acetylcholine release stimulant | 0.129 0.036 DBMET00531 0.127 0.039 DBMET00532 0.112 0.061 DBMET00625 0.102 0.083 DBMET00489 | DBMET00531 | |
| 0.011 | 0.598 | 0.202 | Mcl-1 antagonist | 0.202 0.054 DBMET00625 | DBMET00625 | |
| 0.011 | 0.601 | 0.155 | Estrogen receptor beta antagonist | 0.155 0.014 DBMET00625 | DBMET00625 | |
| 0.005 | 0.596 | 0.069 | Alpha 2 adrenoreceptor agonist | 0.069 0.032 DBMET00625 | DBMET00625 | |
| 0.009 | 0.609 | 0.078 | Acetyl-CoA transferase 2 inhibitor | 0.078 0.011 DBMET00625 | DBMET00625 | |
| 0.005 | 0.606 | 0.079 | Nicotinic alpha4beta2 receptor antagonist | 0.076 0.054 DBMET00531 0.079 0.051 DBMET00532 | DBMET00532 | |
| 0.018 | 0.619 | 0.45 | Lipoxygenase inhibitor | 0.45 0.026 DBMET00625 | DBMET00625 | |
| 0.02 | 0.623 | 0.219 | Farnesoid X receptor antagonist | 0.219 0.017 DBMET00625 | DBMET00625 | |
| 0.01 | 0.615 | 0.048 | Aldosterone antagonist | 0.048 0.032 DBMET00531 0.047 0.033 DBMET00532 | DBMET00531 | |
| 0.006 | 0.611 | 0.094 | Adrenaline agonist | 0.094 0.041 DBMET00625 0.076 0.063 DBMET00489 | DBMET00625 | |
| 0.02 | 0.638 | 0.125 | Neuropeptide Y1 antagonist | 0.125 0.112 DBMET00625 | DBMET00625 | |
| 0.003 | 0.624 | 0.029 | MAP3K8 inhibitor | 0.028 0.024 DBMET00531 0.029 0.02 DBMET00532 | DBMET00532 | |
| 0.003 | 0.625 | 0.043 | Leukotriene D4 antagonist | 0.043 0.011 DBMET00625 | DBMET00625 | |
| 0.014 | 0.636 | 0.087 | Alpha 2c adrenoreceptor antagonist | 0.087 0.079 DBMET00625 | DBMET00625 | |
| 0.019 | 0.644 | 0.128 | Thiol protease inhibitor | 0.124 0.109 DBMET00532 0.128 0.1 DBMET00625 | DBMET00625 | |
| 0.016 | 0.661 | 0.388 | Calpain 2 inhibitor | 0.388 0.068 DBMET00625 | DBMET00625 | |
| 0.023 | 0.669 | 0.403 | 15-Lipoxygenase inhibitor | 0.403 0.073 DBMET00625 | DBMET00625 | |
| 0.012 | 0.658 | 0.508 | Elastase 1 inhibitor | 0.508 0.001 DBMET00489 | DBMET00489 | |
| 0.01 | 0.659 | 0.115 | Uric acid excretion stimulant | 0.115 0.041 DBMET00625 | DBMET00625 | |
| 0.02 | 0.674 | 0.132 | Nav1.1 sodium channel blocker | 0.132 0.041 DBMET00625 | DBMET00625 | |
| 0.025 | 0.68 | 0.255 | Antiobesity | 0.255 0.152 DBMET00625 | DBMET00625 | |
| 0.005 | 0.662 | 0.033 | Protein kinase (CK2) beta inhibitor | 0.033 0.024 DBMET00531 0.032 0.025 DBMET00532 0.031 0.03 DBMET00489 | DBMET00531 | |
| 0.016 | 0.674 | 0.239 | 5 Hydroxytryptamine 1E antagonist | 0.238 0.088 DBMET00531 0.239 0.086 DBMET00532 0.192 0.14 DBMET00625 | DBMET00532 | |
| 0.013 | 0.672 | 0.09 | Alpha 2b adrenoreceptor antagonist | 0.09 0.085 DBMET00625 | DBMET00625 | |
| 0.044 | 0.704 | 0.234 | Caspase 3 stimulant | 0.234 0.127 DBMET00625 | DBMET00625 | |
| 0.006 | 0.667 | 0.038 | Tryptophan 5 hydroxylase inhibitor | 0.037 0.022 DBMET00531 0.037 0.021 DBMET00532 0.038 0.019 DBMET00489 | DBMET00489 | |
| 0.034 | 0.696 | 0.274 | Insulysin inhibitor | 0.274 0.076 DBMET00531 0.272 0.078 DBMET00532 0.272 0.077 DBMET00625 0.266 0.083 DBMET00489 | DBMET00531 | |
| 0.01 | 0.673 | 0.059 | Glucose-6-phosphate translocase inhibitor | 0.059 0.025 DBMET00625 | DBMET00625 | |
| 0.004 | 0.672 | 0.531 | Macrophage elastase inhibitor | 0.531 0.003 DBMET00489 | DBMET00489 | |
| 0.027 | 0.697 | 0.175 | CF transmembrane conductance regulator agonist | 0.174 0.043 DBMET00531 0.175 0.042 DBMET00532 0.169 0.047 DBMET00625 0.158 0.062 DBMET00489 | DBMET00532 | |
| 0.025 | 0.701 | 0.201 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.201 0.018 DBMET00625 | DBMET00625 | |
| 0.025 | 0.702 | 0.218 | Neuropeptide Y2 antagonist | 0.191 0.137 DBMET00531 0.204 0.112 DBMET00532 0.218 0.091 DBMET00625 | DBMET00625 | |
| 0.007 | 0.685 | 0.033 | Estrogen-related receptor beta antagonist | 0.033 0.021 DBMET00625 | DBMET00625 | |
| 0.01 | 0.692 | 0.171 | I kappa B kinase epsilon inhibitor | 0.145 0.125 DBMET00531 0.147 0.122 DBMET00532 0.171 0.098 DBMET00625 | DBMET00625 | |
| 0.013 | 0.696 | 0.048 | Sodium/calcium exchanger inhibitor | 0.048 0.038 DBMET00532 | DBMET00532 | |
| 0.002 | 0.688 | 0.046 | Estrogen receptor alpha agonist | 0.046 0.018 DBMET00625 | DBMET00625 | |
| 0.059 | 0.748 | 0.315 | Interleukin 2 agonist | 0.315 0.064 DBMET00625 | DBMET00625 | |
| 0.009 | 0.707 | 0.076 | Myeloperoxidase inhibitor | 0.076 0.074 DBMET00532 0.076 0.074 DBMET00625 | DBMET00625 | |
| 0.003 | 0.704 | 0.07 | Alpha adrenoreceptor agonist | 0.07 0.045 DBMET00625 | DBMET00625 | |
| 0.006 | 0.711 | 0.196 | Cyclooxygenase 2 inhibitor | 0.196 0.032 DBMET00625 | DBMET00625 | |
| 0.012 | 0.718 | 0.089 | Bromodomain-containing protein 2 inhibitor | 0.089 0.057 DBMET00531 0.089 0.056 DBMET00532 | DBMET00532 | |
| 0.006 | 0.719 | 0.076 | Caspase 7 inhibitor | 0.076 0.071 DBMET00531 0.075 0.073 DBMET00532 0.075 0.074 DBMET00625 | DBMET00531 | |
| 0.006 | 0.725 | 0.052 | Glucosylceramidase inhibitor | 0.052 0.044 DBMET00532 0.05 0.048 DBMET00489 | DBMET00532 | |
| 0.01 | 0.736 | 0.157 | Focal adhesion kinase 2 inhibitor | 0.157 0.12 DBMET00532 | DBMET00532 | |
| 0.011 | 0.737 | 0.074 | CXC chemokine 1 receptor antagonist | 0.074 0.01 DBMET00625 | DBMET00625 | |
| 0.004 | 0.736 | 0.084 | Protein kinase C zeta inhibitor | 0.084 0.077 DBMET00625 | DBMET00625 | |
| 0.008 | 0.743 | 0.043 | CC chemokine 4 receptor antagonist | 0.043 0.04 DBMET00532 | DBMET00532 | |
| 0.071 | 0.81 | 0.414 | Calcium channel L-type activator | 0.414 0.072 DBMET00625 | DBMET00625 | |
| 0.004 | 0.751 | 0.089 | Inducible nitric-oxide synthase inhibitor | 0.089 0.049 DBMET00625 | DBMET00625 | |
| 0.004 | 0.754 | 0.032 | Liver X receptor alpha antagonist | 0.032 0.016 DBMET00625 | DBMET00625 | |
| 0.011 | 0.762 | 0.178 | DNA methyltransferase I inhibitor | 0.178 0.081 DBMET00625 | DBMET00625 | |
| 0.005 | 0.759 | 0.209 | Prostaglandin dehydrogenase inhibitor | 0.191 0.162 DBMET00625 0.209 0.151 DBMET00489 | DBMET00489 | |
| 0.005 | 0.765 | 0.092 | Platelet activating factor antagonist | 0.092 0.086 DBMET00532 | DBMET00532 | |
| 0.009 | 0.771 | 0.149 | Platelet aggregation inhibitor | 0.149 0.129 DBMET00532 | DBMET00532 | |
| 0.005 | 0.77 | 0.104 | Nitric-oxide synthase inhibitor | 0.104 0.054 DBMET00625 | DBMET00625 | |
| 0.005 | 0.797 | 0.134 | Leukotriene synthesis inhibitor | 0.134 0.012 DBMET00625 | DBMET00625 | |
| 0.004 | 0.801 | 0.031 | Liver X receptor antagonist | 0.031 0.021 DBMET00625 | DBMET00625 | |
| 0.009 | 0.812 | 0.2 | Antipruritic | 0.2 0.049 DBMET00625 | DBMET00625 | |
| 0.004 | 0.824 | 0.089 | Lipase inhibitor | 0.089 0.035 DBMET00625 | DBMET00625 | |
| 0.004 | 0.833 | 0.451 | 5-Lipoxygenase inhibitor | 0.451 0.005 DBMET00625 | DBMET00625 | |
| 0.013 | 0.846 | 0.125 | Electron transport complex I inhibitor | 0.125 0.041 DBMET00625 | DBMET00625 | |
| 0.01 | 0.844 | 0.268 | Chymotrypsin inhibitor | 0.073 0.066 DBMET00625 0.268 0.005 DBMET00489 | DBMET00489 | |
| 0.051 | 0.894 | 0.166 | Peptidyltransferase inhibitor | 0.166 0.155 DBMET00625 | DBMET00625 | |
| 0.005 | 0.852 | 0.229 | Interleukin antagonist | 0.22 0.074 DBMET00625 0.229 0.07 DBMET00489 | DBMET00489 | |
| 0.002 | 0.857 | 0.03 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.03 0.029 DBMET00625 | DBMET00625 | |
| 0.004 | 0.89 | 0.234 | Alpha-glucosidase inhibitor | 0.234 0.197 DBMET00625 | DBMET00625 | |
| 0.021 | 0.933 | 0.193 | NOS3 expression enhancer | 0.193 0.044 DBMET00625 | DBMET00625 | |
| 0.005 | 0.937 | 0.355 | Streptokinase A inhibitor | 0.355 0.06 DBMET00625 | DBMET00625 | |
| 0.036 | 0.976 | 0.213 | ErbB-1 antagonist | 0.213 0.077 DBMET00625 | DBMET00625 | |
| 0.005 | 0.971 | 0.106 | M18 aspartyl aminopeptidase inhibitor | 0.106 0.085 DBMET00625 | DBMET00625 | |
| 0.004 | 0.982 | 0.174 | Amyloid beta precursor protein antagonist | 0.174 0.077 DBMET00625 | DBMET00625 | |
| 0.004 | 0.981 | 0.099 | Bronchodilator | 0.099 0.065 DBMET00625 | DBMET00625 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |